WO2022106714A1 - Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases - Google Patents
Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases Download PDFInfo
- Publication number
- WO2022106714A1 WO2022106714A1 PCT/EP2021/082619 EP2021082619W WO2022106714A1 WO 2022106714 A1 WO2022106714 A1 WO 2022106714A1 EP 2021082619 W EP2021082619 W EP 2021082619W WO 2022106714 A1 WO2022106714 A1 WO 2022106714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- fbvm
- volume
- mobile phase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- 230000001713 cholinergic effect Effects 0.000 title claims abstract description 16
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000001727 in vivo Methods 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 3
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 3
- 230000036592 analgesia Effects 0.000 claims abstract description 3
- 208000035475 disorder Diseases 0.000 claims abstract description 3
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 3
- 201000003723 learning disability Diseases 0.000 claims abstract description 3
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 20
- 239000011541 reaction mixture Substances 0.000 claims description 20
- -1 fluorine ions Chemical class 0.000 claims description 12
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 10
- 239000005695 Ammonium acetate Substances 0.000 claims description 10
- 235000019257 ammonium acetate Nutrition 0.000 claims description 10
- 229940043376 ammonium acetate Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 7
- 238000006193 diazotization reaction Methods 0.000 claims description 5
- 238000006795 borylation reaction Methods 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 150000008049 diazo compounds Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 235000010288 sodium nitrite Nutrition 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 108091006774 SLC18A3 Proteins 0.000 description 19
- 102100039452 Vesicular acetylcholine transporter Human genes 0.000 description 19
- 239000000700 radioactive tracer Substances 0.000 description 15
- 229910052717 sulfur Inorganic materials 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 238000002600 positron emission tomography Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000626 neurodegenerative effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 210000002932 cholinergic neuron Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- YSSBJODGIYRAMI-UHFFFAOYSA-N vesamicol Chemical compound OC1CCCCC1N1CCC(C=2C=CC=CC=2)CC1 YSSBJODGIYRAMI-UHFFFAOYSA-N 0.000 description 3
- YSSBJODGIYRAMI-IAGOWNOFSA-N (1R,2R)-2-(4-phenyl-1-piperidinyl)-1-cyclohexanol Chemical compound O[C@@H]1CCCC[C@H]1N1CCC(C=2C=CC=CC=2)CC1 YSSBJODGIYRAMI-IAGOWNOFSA-N 0.000 description 2
- FHYAUNJNVMGZQN-NHCUHLMSSA-N (2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(I)C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 FHYAUNJNVMGZQN-NHCUHLMSSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- JJYKJUXBWFATTE-UHFFFAOYSA-M 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate Chemical compound COC(C([O-])=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-M 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 2
- XISXRVFRLOWUBM-UHFFFAOYSA-N 5,8-dihydronaphthalen-1-amine Chemical compound C1C=CCC2=C1C=CC=C2N XISXRVFRLOWUBM-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000711 polarimetry Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JJYKJUXBWFATTE-SECBINFHSA-N (2r)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid Chemical compound CO[C@](C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-SECBINFHSA-N 0.000 description 1
- QDERQSYUBLZZNW-OTUYWUNPSA-N (2r,3r)-5-(2-fluoranylethoxy)-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(OCC[18F])C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 QDERQSYUBLZZNW-OTUYWUNPSA-N 0.000 description 1
- FUPIVZHYVSCYLX-UHFFFAOYSA-N 1,4-dihydronaphthalene Chemical compound C1=CC=C2CC=CCC2=C1 FUPIVZHYVSCYLX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- YSSBJODGIYRAMI-SETVJMCQSA-N 4-phenyl-1-(2-tritiooxycyclohexyl)piperidine Chemical compound [3H]OC1CCCCC1N1CCC(C=2C=CC=CC=2)CC1 YSSBJODGIYRAMI-SETVJMCQSA-N 0.000 description 1
- CELYMPNBUOGKMD-UHFFFAOYSA-N 5-amino-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1C=2C(N)=CC=CC=2CC(O)C1N(CC1)CCC1C1=CC=CC=C1 CELYMPNBUOGKMD-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 238000007045 Balz-Schiemann reaction Methods 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000006506 Brasenia schreberi Nutrition 0.000 description 1
- 241000039077 Copula Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241000801593 Pida Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- JJYKJUXBWFATTE-UHFFFAOYSA-N mosher's acid Chemical compound COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010085082 sigma receptors Proteins 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- the subject of the present invention is new compounds radiolabeled with fluorine-18, their method of preparation as well as their uses, in particular for the diagnosis of cholinergic neurodegenerative diseases.
- VAChT vesicular acetylcholine transporter
- AD Alzheimer's disease
- VAChT progressive supranuclear palsy
- the exploration of the VAChT has an interest both for the diagnosis and the follow-up of the neurodegenerative conditions mentioned above. It can be considered complementary to the imaging of abnormal proteins characteristic of these diseases. For example, the presence of beta-amyloid plaques detected by imaging is not always correlated with the intensity of clinical scores in Alzheimer's disease (e.g. Stephen et al. J Alzheimers Dis. 2017;59(2) :695-705.doi:10.3233/JAD-170092). On the other hand, an alteration of the cholinergic systems is necessarily linked to neuropsychiatric symptoms (e.g. Sultzer et al. Brain. 2018 Mar 1;141 (3):626-628. doi: 10.1093/brain/awy040).
- VAChT in vivo exploration of VAChT makes it possible to highlight, during Alzheimer's disease, a cholinergic denervation which is more sensitive and better correlated with cognitive symptoms than exploration of p-amyloid plaques or brain metabolism (Aghourian et al. Mol Psychiatry. 2017 Nov;22(1 1 ):1531 -1538. doi: 10.1038/mp.2017.183.).
- the object of the present invention is therefore to provide a new radiolabelled compound allowing the diagnosis of cholinergic neurodegenerative diseases.
- the present invention also aims to provide a compound for the diagnosis of cholinergic neurodegenerative diseases, suitable for positron emission tomography (PET).
- PET positron emission tomography
- the present invention also aims to provide an effective in vivo PET tracer with a very good passage of the blood-brain barrier and a specific accumulation in the brain regions where the VAChTs are located, and exhibiting good stability in vivo.
- the compound of formula (I) according to the invention is a radiolabeled compound and corresponds to the radiolabeled (R, R) enantiomer of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3, 4-tetrahydronaphthalen-2-ol (FBVM).
- This compound is also called (-)-(R,R)-5-[18F] -FBVM .
- the compound of formula (I) according to the invention is optically pure.
- the present invention also relates to the compound of formula (I) as defined above, for use in an in vivo diagnostic method.
- the present invention also relates to the compound of formula (I) as defined above, for its use in an in vivo diagnostic method for a cholinergic neurodegenerative disease.
- the cholinergic neurodegenerative disease is selected from the group consisting of Alzheimer's disease, dysmnesia, learning disability, schizophrenia, cognitive dysfunction, hyperactivity disorder, neurosis anxiety, depression, analgesia and Parkinson's disease.
- the invention makes it possible to lift the lock of early diagnosis, that is to say before the appearance of clinical signs, of neurodegenerative conditions such as Alzheimer's disease, thanks to quantitative in vivo imaging of the VAChT, the reduction of which is a sensitive index of the loss of cholinergic neurons associated with the subsequent appearance, from a certain threshold of loss of cholinergic neurons, of the cognitive disorders characteristic of the disease.
- This early detection is a major issue because the treatments, very actively sought, will be all the more effective if they are administered in the early stages of the disease, the asymptomatic phases.
- the (-)-(R,R)-5-[ 18 F]FBVM according to the invention is not or very unlikely to lose its radioactive fluorine unlike 5- [ 18 F ]FEOBV which is radiolabeled in the aliphatic position.
- the optically pure fluorine-18 radiolabeled molecule according to the invention binds specifically to VAChT.
- the present invention based on the structure of molecules of the (benzo)vesamicol type, makes it possible to achieve a good level of specificity in vitro, and the first radioligand has already demonstrated its potential as a PET tracer in vivo in rat with regard to its excellent passage through the blood-brain barrier, its specific accumulation in the cerebral regions where the VAChTs are located and its good stability in vivo.
- the compound of formula (I) according to the invention can therefore also be used as a tracer for the PET quantification of VAChT.
- the compound of formula (I) according to the invention can also be used as a reagent for the mapping of VAChT (radioactive indicator) or the like, which can be used for positron emission tomography (PET).
- VAChT radioactive indicator
- PET positron emission tomography
- the compound of the invention can also be used to monitor and control the progression of the aforementioned diseases or to follow the effectiveness of the treatment of these diseases.
- the present invention also relates to a process for preparing the compound of formula (I) as defined above, comprising a step (a) of preparation of a reaction mixture by adding a compound of formula (III) below: with 18 F reactive fluorine ions, followed by a step (b) of chiral separation of said reaction mixture obtained at the end of step (a).
- step (a) is carried out in the presence of Cu(OTf) 2 .
- step (a) is carried out in a mixture of DMF and pyridine as solvent.
- step (a) of the process of the invention is carried out in the presence of Cu(OTf) 2 in a mixture of DMF and pyridine.
- step (a) comprises a step of heating the reaction mixture to a temperature of 90°C to 120°C, preferably equal to 100°C.
- this heating is carried out for a period of between 2 minutes and 30 minutes, preferably equal to 10 minutes.
- the above-mentioned heating step is followed by a cooling step to a temperature between 25°C and 40°C, preferably equal to 30°C.
- step (a) of the process of the invention comprises a step of heating the reaction mixture, to a temperature of from 90° C. to 120° C., preferably equal to 100° C., for a duration comprised from 2 minutes to 30 minutes, preferably equal to 10 minutes, said heating step being preferably followed by a cooling step to a temperature comprised from 25°C to 40°C, preferably equal to 30°C .
- step (b) of chiral separation is carried out by loading the reaction mixture obtained at the end of step (a) onto a semi-preparative chiral column whose stationary phase is chiral, in particular Chiral pak IA, Daicel 10*250 mm.
- a mobile phase comprising a mixture of acetonitrile, ammonium acetate and methanol is preferably used.
- the mobile phase comprises from 50% to 90% by volume of acetonitrile, from 0% to 20% by volume of ammonium acetate and from 0% to 40% by volume of methanol, the percentages being calculated by relative to the total volume of said mobile phase.
- a preferred mobile phase according to the invention comprises 70% by volume of acetonitrile, 10% by volume of ammonium acetate and 20% by volume of methanol, the percentages being calculated with respect to the total volume of said mobile phase.
- the compound of formula (III) is obtained by a diazotization reaction of a compound of formula (IV) below followed by a substitution reaction with a halogen, such as iodine, on the diazo compound obtained at the end of the aforementioned diazotization reaction,
- the compound of formula (III) is obtained according to a process comprising the following steps:
- the above reaction step is preferably carried out in acetonitrile, especially at room temperature.
- this reaction step is carried out for 4 hours.
- the stage of transformation of the compound of formula (V) is preferably carried out in the presence of potassium acetate in solvents of the amide type, such as for example DMA or DMF, and preferentially DMF.
- the abovementioned reaction step is preferably carried out at a temperature of 80° C. to 110° C., preferably equal to 90° C., until the starting material has disappeared, and in particular for 1 hour.
- the present invention also relates to the compound of formula (II) below:
- the compound of formula (II) according to the invention is a radiolabeled compound and corresponds to the radiolabeled (S,S) enantiomer of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3, 4-tetrahydronaphthalen-2-ol (FBVM).
- This compound is also called (+)-(S,S)-5-[18F] -FBVM .
- This compound can be obtained according to the process described above for the compound of formula (I).
- the present invention also relates to the compound corresponding to the formula
- IR 3441, 3372, 3024, 2903, 2841, 2815, 2607, 2591, 1584, 1584, 1567, 1536, 1465, 1430, 1343, 1301, 1246, 1141, 1068, 6,70,8 .
- the mixture was transferred to a separating funnel then the organic layer was separated and washed with brine (100 mL) then a saturated solution of NaHCOs (100 mL), dried over MgSO4, filtered and concentrated for drying under reduced pressure .
- the crude was purified by flash column chromatography on silica gel using EP/AcOEt (80/20) as eluent to obtain the desired product 3 as a pink solid (19.3 g, 89%).
- IR 3277, 3034, 2930, 2900, 2815, 1703, 1610, 1586, 1550, 1467, 1347, 1291, 1256, 1185, 1151, 1068, 915, 782, 767, 700.
- Mp 102-103°C.
- IR 3241, 3143, 3067, 3020, 2918, 2899, 2824, 1723, 1608, 1587, 1545, 1471, 1454, 1423, 1334, 1266, 1155, 1069, 998, 9826, 902,8 8, 92,8 787, 764, 741.
- the 5-R1 trans regioisomer of interest was then engaged in a Balz-Schiemann reaction to give the rac product 5-FBVM Trans with a yield of 59%.
- the latter was transformed into a Mosher ester through commercial (R)-(+)-a-methoxy-a-trifluoromethylphenylacetic acid used as a chiral copula Using the Steglich conditions, the two diastereoisomers 6-D1 and 6-D 2 were obtained and separated with an overall yield of 60%.
- the boronic ester 8 was used as precursor (corresponding to the compound of formula (III) mentioned above). This was synthesized following the synthetic route described in scheme 4.
- the compound 5-Ri Trans was transformed in situ into the corresponding diazonium salt by the action of NaNO 2 in the presence of the monohydrated APTS. The latter leads to the iodinated intermediate 7 Trans under the action of the potassium iodide present in the reaction medium with a yield of 50%.
- the Miyaura borylation conditions subsequently made it possible to transform the 7 Trans intermediate into the desired 8 Trans compound with a yield of 44%.
- the aqueous layer was extracted with AcOEt (3 x 25 mL) and the combined organic phases were dried over MgSC, filtered and then dried under reduced pressure.
- the residue was purified by flash chromatography on a column of silica gel (PE/AcOEt: 85/15) to obtain the desired product 7 in the form of a yellowish solid (587 mg, 50%).
- compound 7 (100 mg, 0.23 mmol) was dissolved in degassed anhydrous DMF (2 mL), then B2Pin 2 (88 mg, 0.35 mmol, 1.5 equivalent) , KOAc (68 mg, 0.69 mmol, 3.0 equivalents) and Pd(dppf)Cl 2 .DCM (19 mg, 0.02 mmol, 0.1 equivalent) were added respectively.
- the tube was sealed under argon and heated at 160°C for 1 hour 30 minutes.
- the reaction mixture was cooled to ambient temperature then the DMF was dried under reduced pressure.
- the residue was washed with brine (20ml) and filtered through a celite pad.
- the filtrate was extracted with AcOEt (3 x 10 mL).
- radiochemistry had enabled the preparation of rac (+/-)-5-FBVM Trans labeled with Fluor 18 and the hot chiral separation of the two isomers it contains. These are the 2 enantiomers labeled with 18 F and named 18 F E1 and 18 F E2 (Diagram 5).
- Diagram 5 Radiolabeling of the 8 Trans derivative with 18 F. Obtaining racemic tracers and enantiopure tracers 18 F E1 and 18 F E2 identified respectively as (-)-(R,R)-5-r 8 F]FBVM and ( +)-(S,S)-5-[ ,8 F]FBVM. Radiosynthesis of rac-18F-5-FBVM, (RR)-(-)-18F-5-FBVM and (S,S)-(+)-18F-5-FBVM
- Fluoride ions [ 18 F] are produced using a cyclotron (PET trace, GE Healthcare) by irradiating a water target enriched in oxygen 18 with a beam of protons by means of the nuclear reaction 18 O (p,n) 18 F.
- the [ 18 F] fluoride ions produced are transferred to a modified TRACERIab FX-FN Pro (GE) automaton, passed over an anion exchange cartridge (Waters Sep-Pak Accell Light QMA conditioned with using a solution of potassium carbonate).
- the trapped [ 18 F] fluoride ions are eluted from the cartridge by 550 ⁇ L of a solution containing KOTf (5 mg) and K2CO3 (50 ⁇ g).
- Azeotropic distillation is then carried out by adding 1 mL of acetonitrile. The evaporation of the water is carried out at 90° C. under helium flow and under depression and this operation is repeated twice before carrying out the nucleophilic substitution.
- Precursor 8 (2 mg) with Cu(OTf) 2 (3.6 mg) dissolved in DMF (960 pL) and pyridine (40 pL) are added to the fluoride ions [ 18 F], The mixture is brought to 100 °C for 10 min then cooled to 30°C and diluted with water (8 mL). The reaction mixture is passed through a tC18 plus cartridge (Waters) then rinsed with water (4 mL) to trap the product of interest and eliminate most of the polar compounds.
- the (+/-) [ 18 F]-5-FBVM is eluted from the cartridge with acetonitrile (2 mL) and the solution diluted with 0.1 M ammonium acetate (1 mL).
- the solution obtained is loaded into the HPLC injection loop of the automaton and purified on a semi-preparative column (PhenylHexyl - Phenomenex, 10 x 250 mm) with an ACN/0.1 M ammonium acetate mixture as mobile phase. 70/30 at a flow rate of 4 mL.min -1 . Under these conditions the (+/-) [ 18 F]-5-FBVM was collected with a retention time of the order of 11 min.
- the fraction collected was diluted with water (30 mL) then passed through a tC18 light cartridge (Waters) then the cartridge was rinsed with water (5 mL).
- the (+/-) [ 18 F]-5-FBVM is eluted from the cartridge with injectable ethanol (0.8 mL) and the formulation is completed by adding 7.2 mL of NaCl (0. 9%).
- (+)[18F]-5- FBVM and (-)[18F]-5- FBVM enantiomers follows the manufacturing process of (+/-)[18F]-5- FBVM by adding a chiral HPLC purification.
- the collected pure fraction of (+/-) [ 18 F]-5-FBVM is loaded into the HPLC loop of the automaton to carry out a new HPLC purification, this time on a chiral semi-preparative column (Chriralpak IA, Daicel , 10x250mm).
- the mobile phase used consists of acetonitrile/ammonium acetate: 0.1 M 85/15 and the purification is carried out at 4 mL.min ⁇ 1 .
- the (-) [ 18 F]-5-FBVM is collected with a retention time of approximately 18 min when the (+) [ 18 F]-5-FBVM exhibits a retention time of approximately 22 min.
- each pure enantiomer can be produced separately.
- the enantiomerically pure fraction collected, the (-) or (+) [ 18 F]-5-FBV is diluted with water (30 mL) then passed through a tC18 light cartridge (Waters). The cartridge is rinsed with water (5 mL).
- the (-) [ 18 F]-5-FBVM or (+) [ 18 F]-5-FBVM is eluted from the cartridge by injectable ethanol (0.8 mL) and the formulation is completed by adding of 7.2 mL of NaCl (0.9%).
- the process repeats that described above up to the purification stage.
- the crude solution of (+/-) [ 18 F]-5-FBVM is loaded into the HPLC loop and injected onto the chiral column (Chiralpak IA, Daicel, 10 ⁇ 250 mm).
- the purification is carried out using a mixture of acetonitrile/methanol/0.1 M ammonium acetate: 70/10/20 as mobile phase and at a flow rate of 4 mL/min. Under these conditions, the retention time of (-)-(R,R)-[18F]-5- FBVM of the order of 14.5 min.
- the formulation incorporates the methods presented above.
- the radiotracers were controlled by analytical HPLC equipped with a UV and radio detector.
- the purity (+/-) [18F]-5-FBVM was checked using an analytical column (Phenomenex Luna 5p Phenyl Hexyl 4.6x250 mm) using ACN/Ac Am 0.1 M 70 /30 as mobile phase and a flow rate of 1 mL/min. Under these conditions, the retention time is 9 min.
- the radiochemical purity was greater than 99%, the molar activity greater than 100 GBq/pmole and no degradation was observed in the formulation media as in the serum for at least 4 h.
- the present invention based on the structure of molecules of the (benzo)vesamicol type makes it possible to achieve a good level of specificity in vitro, and the first radioligand (rac (+/-)-5-FBVM T rans) has demonstrated its potential as PET tracer in vivo in rats with regard to its excellent passage through the blood- encephalon, its specific accumulation in the cerebral regions where the VAChTs are located and its good stability in vivo.
- Rats in the control group received an i.v. injection of tracer (4-6 MBq in 0.3 mL) under isofuran gas anesthesia (n 6/group).
- the biological samples are then weighed and their radioactivity is measured with a y counter (2480 Gamma counter Wizard, Perkin Elmer), and the percentage of injected dose/g of tissue (%ID/g) is calculated.
- PET imaging The rats received an iv injection of 37 MBq of the tracer.
- the acquisitions were carried out with a microPET explore VISTA-CT system imaging system (GE Healthcare, France) under isoflurane anesthesia (Baxter, France), at 4-5% in oxygen for induction then 1.5 -2% while recording.
- Each acquisition lasted 91 minutes and the images were sequenced in list-mode in 1 sequence of 1 min followed by 9 sequences of 10 min.
- the images were reconstructed according to a 2-D OSEM algorithm (GE Healthcare, France) in voxels of 0.3875 ⁇ 0.3875 ⁇ 0.775 mm 3 .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The present invention relates to the radiolabelled compound of enantiomer (R, R) of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol, as well as said compound for use in a method for in-vivo diagnosis of, in particular, a cholinergic neurodegenerative disease, for example chosen from the group consisting of Alzheimer's disease, dysmnesia, learning disabilities, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgesia and Parkinson's disease.
Description
COMPOSÉS RADIOMARQUÉS POUR LE DIAGNOSTIC DE MALADIES NEURODÉGÉNÉRATIVES CHOLINERGIQUES RADIOLABELED COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE CHOLINERGIC DISEASES
La présente invention a pour objet de nouveaux composés radiomarqués au fluor- 18, leur procédé de préparation ainsi que leurs utilisations, notamment pour le diagnostic de maladies neurodégénératives cholinergiques. The subject of the present invention is new compounds radiolabeled with fluorine-18, their method of preparation as well as their uses, in particular for the diagnosis of cholinergic neurodegenerative diseases.
Les systèmes cholinergiques sont impliqués dans de multiples fonctions, et de nombreuses informations ont été obtenues ces dernières années sur les mécanismes de la synthèse, du stockage, de la dégradation et des effets de l’acétylcholine sur les nombreux sous-types de récepteurs muscariniques et cholinergiques. Dans ce contexte, le transporteur vésiculaire de l’acétylcholine (VAChT) joue un rôle majeur qui, associé à sa localisation dans les terminaisons des neurones cholinergiques, en fait une cible de choix pour l’étude du fonctionnement et de l’intégrité des systèmes cholinergiques. Au niveau central ces systèmes sont particulièrement impliqués dans les processus cognitifs, et l’exploration in vivo du VAChT a un intérêt à la fois pour le diagnostic et le suivi des affections neurodégénératives associées à des altérations de ces processus. C’est le cas de la maladie d’Alzheimer (MA), qui est la cause de démence la plus fréquente, touche actuellement 900 000 personnes en France, et constitue un problème de santé publique de plus en plus aigu en raison du vieillissement de la population. De plus, des dysfonctionnements des systèmes cholinergiques se traduisant par des modifications de l’expression du VAChT ont été décrits dans d’autres affections neurodégénératives telles que la démence Parkinsonienne (Kotagal et al. Neurosci Lett. 2012 Apr 18;514(2):169-72. doi: 10.1016/j.neulet.2O12.02.083, Kuhl et al Ann Neurol. 1996 Sep;40(3):399-410. doi: 10.1002/ana.410400309), la paralysie supranucléaire progressive (Mazère et al. Radiology. 2012 Nov;265(2):537-43. doi: 10.1 148/radiol.121 12650), l’atrophie multisystématisée (Mazère et al. Neuroimage Clin. 2013 Aug 8;3:212-7. doi: 10.1016/j.nicl.2O13.07.012), la démence à corps de Lewy (Mazère et al. J Nucl Med. 2017 Jan;58(1 ) :123-128. doi: 10.2967/jnumed.116.176180 ; Nejad-Davarani et al. Mol Psychiatry. 2019 Mar;24(3):322-327. doi: 10.1038/s41380-018-0130-5), ou dans des affections périphériques telles que le cancer (Stokholm et al. Eur J Nucl Med Mol Imaging. 2016 May;43(5):906-910. doi: 10.1007/s00259-015-3143-1 ) ou les affections cardiaques (Durand et al. Am J Physiol Heart Cire Physiol. 2015 Aug 15;309(4):H655-62. doi: 10.1 152/ajpheart.00114.2015).
La méthode la plus pertinente pour l’exploration du VAChT in vivo est la tomographie par émission de positrons (TEP), qui impose de disposer de traceurs émetteurs de rayonnement beta+, en particulier le fluor-18 (18F), spécifique de la cible moléculaire d’intérêt. Cholinergic systems are involved in multiple functions, and much information has been obtained in recent years on the mechanisms of the synthesis, storage, degradation and effects of acetylcholine on the many subtypes of muscarinic receptors and cholinergics. In this context, the vesicular acetylcholine transporter (VAChT) plays a major role which, together with its location in the terminals of cholinergic neurons, makes it a target of choice for studying the functioning and integrity of neuronal systems. cholinergics. At the central level, these systems are particularly involved in cognitive processes, and the in vivo exploration of VAChT is of interest both for the diagnosis and the monitoring of neurodegenerative conditions associated with alterations in these processes. This is the case of Alzheimer's disease (AD), which is the most frequent cause of dementia, currently affects 900,000 people in France, and constitutes an increasingly acute public health problem due to the aging of population. Additionally, dysfunctions of cholinergic systems resulting in changes in VAChT expression have been described in other neurodegenerative conditions such as Parkinsonian dementia (Kotagal et al. Neurosci Lett. 2012 Apr 18;514(2): 169-72. doi: 10.1016/j.neulet.2O12.02.083, Kuhl et al Ann Neurol. 1996 Sep;40(3):399-410. doi: 10.1002/ana.410400309), progressive supranuclear palsy (Mazère and al. Radiology. 2012 Nov;265(2):537-43. doi: 10.1 148/radiol.121 12650), multiple system atrophy (Mazère et al. Neuroimage Clin. 2013 Aug 8;3:212-7. doi : 10.1016/j.nicl.2O13.07.012), Lewy body dementia (Mazère et al. J Nucl Med. 2017 Jan;58(1):123-128. doi: 10.2967/jnumed.116.176180; Nejad-Davarani et al. Mol Psychiatry. 2019 Mar;24(3):322-327. doi:10.1038/s41380-018-0130-5), or in peripheral conditions such as cancer (Stokholm et al. Eur J Nucl Med Mol Imaging.2016 May;43(5):906-910.doi:10.1007/s00259-015-3143-1) or the heart disease (Durand et al. Am J Physiol Heart Wax Physiol. 2015 Aug 15;309(4):H655-62. doi:10.1152/ajphead.00114.2015). The most relevant method for the exploration of VAChT in vivo is positron emission tomography (PET), which requires the availability of tracers emitting beta+ radiation, in particular fluorine-18 ( 18 F), specific for the target. molecule of interest.
L’exploration du VAChT a un intérêt à la fois pour le diagnostic et le suivi des affections neurodégénératives citées plus haut. Elle peut être considérée comme complémentaire de l’imagerie des protéines anormales caractéristiques de ces maladies. Par exemple, une présence de plaques beta-amyloïdes détectée par imagerie n’est pas toujours corrélée à l’intensité des scores cliniques au cours de la maladie d’Alzheimer (e.g. Stephen et al. J Alzheimers Dis. 2017;59(2):695-705. doi: 10.3233/JAD-170092). En revanche, une altération des systèmes cholinergiques est obligatoirement liée à des symptômes neuropsychiatriques (e.g. Sultzer et al. Brain. 2018 Mar 1 ;141 (3):626-628. doi: 10.1093/brain/awy040). Dans ce contexte, une étude très récente vient de démontrer que l’exploration in vivo du VAChT permet de mettre en évidence, au cours de la maladie d’Alzheimer, une dénervation cholinergique qui est plus sensible et mieux corrélée aux symptômes cognitifs que l’exploration des plaques p-amyloïdes ou du métabolisme cérébral (Aghourian et al. Mol Psychiatry. 2017 Nov;22(1 1 ):1531 -1538. doi: 10.1038/mp.2017.183.). The exploration of the VAChT has an interest both for the diagnosis and the follow-up of the neurodegenerative conditions mentioned above. It can be considered complementary to the imaging of abnormal proteins characteristic of these diseases. For example, the presence of beta-amyloid plaques detected by imaging is not always correlated with the intensity of clinical scores in Alzheimer's disease (e.g. Stephen et al. J Alzheimers Dis. 2017;59(2) :695-705.doi:10.3233/JAD-170092). On the other hand, an alteration of the cholinergic systems is necessarily linked to neuropsychiatric symptoms (e.g. Sultzer et al. Brain. 2018 Mar 1;141 (3):626-628. doi: 10.1093/brain/awy040). In this context, a very recent study has just demonstrated that the in vivo exploration of VAChT makes it possible to highlight, during Alzheimer's disease, a cholinergic denervation which is more sensitive and better correlated with cognitive symptoms than exploration of p-amyloid plaques or brain metabolism (Aghourian et al. Mol Psychiatry. 2017 Nov;22(1 1 ):1531 -1538. doi: 10.1038/mp.2017.183.).
Seul le iodobenzovésamicol marqué à l’iode-123 ([123I]IBVM) a été qualifié à ce jour comme marqueur d’imagerie utile dans la quantification de la densité en VAChT dans le cerveau (Mazère et al. Neuroimage. 2008 Mar 1 ;40(1 ):280-8. doi: 10.1016/j.neuroimage.2007.1 1 .028). Cependant cette molécule a montré des liaisons non spécifiques, en particulier une liaison aux récepteurs sigma. Par ailleurs ce traceur, marqué à l’iode-123, n’est utilisable qu’en tomographie d’émission monophotonique (SPECT), méthode d’imagerie moléculaire moins adaptée à la quantification in vivo que la TEP. Ces deux points limitent donc l’emploi de l’IBVM comme traceur en clinique. Only iodobenzovesamicol labeled with iodine-123 ([ 123 I]IBVM) has been qualified to date as a useful imaging marker in the quantification of VAChT density in the brain (Mazère et al. Neuroimage. 2008 Mar 1 ;40(1):280-8.doi:10.1016/j.neuroimage.2007.11.028). However, this molecule showed non-specific binding, in particular binding to sigma receptors. Furthermore, this tracer, marked with iodine-123, can only be used in single-photon emission tomography (SPECT), a molecular imaging method less suited to in vivo quantification than PET. These two points therefore limit the use of IBVM as a clinical tracer.
La présente invention a donc pour but de fournir un nouveau composé radiomarqué permettant le diagnostic de maladies neurodégénératives cholinergiques. The object of the present invention is therefore to provide a new radiolabelled compound allowing the diagnosis of cholinergic neurodegenerative diseases.
La présente invention a également pour but de fournir un composé pour le diagnostic de maladies neurodégénératives cholinergiques, adapté à la tomographie par émission de positrons (TEP). The present invention also aims to provide a compound for the diagnosis of cholinergic neurodegenerative diseases, suitable for positron emission tomography (PET).
La présente invention a également pour but de fournir un traceur TEP efficace in vivo avec un très bon passage de la barrière hémato-encéphalique et une
accumulation spécifique dans les régions cérébrales où sont localisés les VAChT, et présentant une bonne stabilité in vivo. The present invention also aims to provide an effective in vivo PET tracer with a very good passage of the blood-brain barrier and a specific accumulation in the brain regions where the VAChTs are located, and exhibiting good stability in vivo.
Ainsi, la présente invention concerne le composé répondant à la formule (I) suivante :
Thus, the present invention relates to the compound corresponding to the following formula (I):
Le composé de formule (I) selon l’invention est un composé radiomarqué et correspond à l’énantiomère radiomarqué (R, R) du 5-fluoro-3-4(-phénylpipéridin-1 -yl)- 1 ,2,3,4-tétrahydronaphthalèn-2-ol (FBVM). The compound of formula (I) according to the invention is a radiolabeled compound and corresponds to the radiolabeled (R, R) enantiomer of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3, 4-tetrahydronaphthalen-2-ol (FBVM).
Ce composé est également nommé (-)-(R,R)-5-[18F]-FBVM. This compound is also called (-)-(R,R)-5-[18F] -FBVM .
Le composé de formule (I) selon l’invention est optiquement pur. The compound of formula (I) according to the invention is optically pure.
La présente invention concerne également le composé de formule (I) telle que définie ci-dessus, pour utilisation dans une méthode de diagnostic in vivo. The present invention also relates to the compound of formula (I) as defined above, for use in an in vivo diagnostic method.
La présente invention concerne également le composé de formule (I) telle que définie ci-dessus, pour son utilisation dans une méthode de diagnostic in vivo d’une maladie neurodégénérative cholinergique. The present invention also relates to the compound of formula (I) as defined above, for its use in an in vivo diagnostic method for a cholinergic neurodegenerative disease.
Selon un mode de réalisation, la maladie neurodégénérative cholinergique est choisie dans le groupe constitué de la maladie d’Alzheimer, de la dysmnésie, du trouble d’apprentissage, de la schizophrénie, du dysfonctionnement cognitif, du trouble d’hyperactivité, de la névrose d’angoisse, de la dépression, de l’analgésie et de la maladie de Parkinson. According to one embodiment, the cholinergic neurodegenerative disease is selected from the group consisting of Alzheimer's disease, dysmnesia, learning disability, schizophrenia, cognitive dysfunction, hyperactivity disorder, neurosis anxiety, depression, analgesia and Parkinson's disease.
Ainsi, l’invention permet de lever le verrou du diagnostic précoce, c’est-à-dire avant l’apparition de signes cliniques, d’affections neurodégénératives telles que la maladie d’Alzheimer, grâce à l’imagerie quantitative in vivo du VAChT dont la diminution est un index sensible de la perte des neurones cholinergiques associée à
l’apparition ultérieure, à partir d’un certain seuil de perte en neurones cholinergiques, des troubles cognitifs caractéristiques de la maladie. Cette détection précoce est un enjeu majeur car les traitements, très activement recherchés, seront d’autant plus efficaces s'ils sont administrés dans les premiers stades de la maladie, les phases asymptomatiques. Thus, the invention makes it possible to lift the lock of early diagnosis, that is to say before the appearance of clinical signs, of neurodegenerative conditions such as Alzheimer's disease, thanks to quantitative in vivo imaging of the VAChT, the reduction of which is a sensitive index of the loss of cholinergic neurons associated with the subsequent appearance, from a certain threshold of loss of cholinergic neurons, of the cognitive disorders characteristic of the disease. This early detection is a major issue because the treatments, very actively sought, will be all the more effective if they are administered in the early stages of the disease, the asymptomatic phases.
En comparaison, par exemple, le 5(-)-[18F]FEOBV (5- fluoroéthoxybenzovésamicol) a été décrit comme traceur TEP ciblant le VAChT (Mulholland et al. 1998). Cependant les inventeurs ont montré un meilleur potentiel du composé de l’invention par rapport à ce produit qui semble être métabolisé plus rapidement, ceci entraînant la dissémination de la radioactivité. De plus l’accumulation dans le cerveau du composé selon l’invention est certes qualitativement similaire à celle du FEOBV mais est quantitativement plus importante. In comparison, for example, 5(-)-[18F] FEOBV (5-fluoroethoxybenzovesamicol) has been described as a PET tracer targeting VChT (Mulholland et al. 1998). However, the inventors have shown a better potential of the compound of the invention compared to this product which seems to be metabolized more quickly, this resulting in the dissemination of radioactivity. Moreover, the accumulation in the brain of the compound according to the invention is certainly qualitatively similar to that of FEOBV but is quantitatively greater.
De par sa structure d’arylfluoré, le (-)-(R,R)-5-[18F]FBVM selon l’invention n’est pas ou très peu susceptible de perdre son fluor radioactif contrairement au 5- [18F]FEOBV qui est lui radiomarqué en position aliphatique. Due to its arylfluorine structure, the (-)-(R,R)-5-[ 18 F]FBVM according to the invention is not or very unlikely to lose its radioactive fluorine unlike 5- [ 18 F ]FEOBV which is radiolabeled in the aliphatic position.
La molécule radiomarquée au fluor-18 optiquement pure selon l’invention, à savoir le composé de formule (I), se lie spécifiquement au VAChT. Comme montré plus loin, la présente invention, basée sur la structure de molécules de type (benzo)vesamicol, permet d’atteindre un bon niveau de spécificité in vitro, et le premier radioligand a déjà démontré son potentiel comme traceur TEP in vivo chez le rat au regard de son excellent passage de la barrière hémato-encéphalique, de son accumulation spécifique dans les régions cérébrales où sont localisés les VAChT et de sa bonne stabilité in vivo. The optically pure fluorine-18 radiolabeled molecule according to the invention, namely the compound of formula (I), binds specifically to VAChT. As shown below, the present invention, based on the structure of molecules of the (benzo)vesamicol type, makes it possible to achieve a good level of specificity in vitro, and the first radioligand has already demonstrated its potential as a PET tracer in vivo in rat with regard to its excellent passage through the blood-brain barrier, its specific accumulation in the cerebral regions where the VAChTs are located and its good stability in vivo.
Le composé de formule (I) selon l’invention peut donc également être utilisé comme traceur pour la quantification en TEP du VAChT. The compound of formula (I) according to the invention can therefore also be used as a tracer for the PET quantification of VAChT.
Le composé de formule (I) selon l’invention peut également être utilisé comme réactif pour la cartographie de VAChT (indicateur radioactif) ou similaire, qui peut être utilisé pour la tomographie par émission de positons (TEP). The compound of formula (I) according to the invention can also be used as a reagent for the mapping of VAChT (radioactive indicator) or the like, which can be used for positron emission tomography (PET).
Le composé de l’invention peut également être utilisé pour surveiller et contrôler la progression des maladies susmentionnées ou pour suivre l’efficacité du traitement de ces maladies. The compound of the invention can also be used to monitor and control the progression of the aforementioned diseases or to follow the effectiveness of the treatment of these diseases.
La présente invention concerne également un procédé de préparation du composé de formule (I) telle que définie ci-dessus, comprenant une étape (a) de
préparation d’un mélange réactionnel par l’addition d’un composé de formule (III) suivante :
avec des ions fluor réactifs 18F, suivie d’une étape (b) de séparation chirale dudit mélange réactionnel obtenu à l’issue de l’étape (a). The present invention also relates to a process for preparing the compound of formula (I) as defined above, comprising a step (a) of preparation of a reaction mixture by adding a compound of formula (III) below: with 18 F reactive fluorine ions, followed by a step (b) of chiral separation of said reaction mixture obtained at the end of step (a).
Selon un mode de réalisation, l’étape (a) est effectuée en présence de Cu(OTf)2. According to one embodiment, step (a) is carried out in the presence of Cu(OTf) 2 .
De préférence, l’étape (a) est effectuée dans un mélange de DMF et de pyridine à titre de solvant. Preferably, step (a) is carried out in a mixture of DMF and pyridine as solvent.
Selon un mode de réalisation, l’étape (a) du procédé de l’invention est effectuée en présence de Cu(OTf)2 dans un mélange de DMF et de pyridine. According to one embodiment, step (a) of the process of the invention is carried out in the presence of Cu(OTf) 2 in a mixture of DMF and pyridine.
Selon un mode de réalisation, l’étape (a) comprend une étape de chauffage du mélange réactionnel, à une température comprise de 90°C à 120°C, de préférence égale à 100°C. According to one embodiment, step (a) comprises a step of heating the reaction mixture to a temperature of 90°C to 120°C, preferably equal to 100°C.
Selon un mode de réalisation, ce chauffage est effectué pendant une durée comprise de 2 minutes à 30 minutes, de préférence égale à 10 minutes. According to one embodiment, this heating is carried out for a period of between 2 minutes and 30 minutes, preferably equal to 10 minutes.
De préférence, l’étape de chauffage susmentionnée est suivie d’une étape de refroidissement à une température comprise de 25°C à 40°C, de préférence égale à 30°C. Preferably, the above-mentioned heating step is followed by a cooling step to a temperature between 25°C and 40°C, preferably equal to 30°C.
Selon un mode de réalisation, l’étape (a) du procédé de l’invention comprend une étape de chauffage du mélange réactionnel, à une température comprise de 90°C à 120°C, de préférence égale à 100°C, pendant une durée comprise de 2 minutes à 30 minutes, de préférence égale à 10 minutes, ladite étape de chauffage étant de préférence suivie d’une étape de refroidissement à une température comprise de 25°C à 40°C, de préférence égale à 30°C.
Selon un mode de réalisation, l’étape (b) de séparation chirale est effectuée par chargement du mélange réactionnel obtenu à l’issue de l’étape (a) sur une colonne chirale semi-préparative dont la phase stationnaire est chirale, notamment Chiral pak IA, Daicel 10*250 mm. According to one embodiment, step (a) of the process of the invention comprises a step of heating the reaction mixture, to a temperature of from 90° C. to 120° C., preferably equal to 100° C., for a duration comprised from 2 minutes to 30 minutes, preferably equal to 10 minutes, said heating step being preferably followed by a cooling step to a temperature comprised from 25°C to 40°C, preferably equal to 30°C . According to one embodiment, step (b) of chiral separation is carried out by loading the reaction mixture obtained at the end of step (a) onto a semi-preparative chiral column whose stationary phase is chiral, in particular Chiral pak IA, Daicel 10*250 mm.
A titre de phase mobile chirale, on utilise de préférence une phase mobile comprenant un mélange d’acétonitrile, d’acétate d’ammonium et de méthanol. As chiral mobile phase, a mobile phase comprising a mixture of acetonitrile, ammonium acetate and methanol is preferably used.
De préférence, la phase mobile comprend de 50% à 90% en volume d’acétonitrile, de 0% à 20% en volume d’acétate d’ammonium et de 0% à 40% en volume de méthanol, les pourcentages étant calculés par rapport au volume total de ladite phase mobile. Preferably, the mobile phase comprises from 50% to 90% by volume of acetonitrile, from 0% to 20% by volume of ammonium acetate and from 0% to 40% by volume of methanol, the percentages being calculated by relative to the total volume of said mobile phase.
Une phase mobile préférée selon l’invention comprend 70% en volume d’acétonitrile, 10% en volume d’acétate d’ammonium et 20% en volume de méthanol, les pourcentages étant calculés par rapport au volume total de ladite phase mobile. A preferred mobile phase according to the invention comprises 70% by volume of acetonitrile, 10% by volume of ammonium acetate and 20% by volume of methanol, the percentages being calculated with respect to the total volume of said mobile phase.
Selon un mode de réalisation, le composé de formule (III) est obtenu par une réaction de diazotation d’un composé de formule (IV) suivante
suivie d’une réaction de substitution par un halogène, tel que l’iode, sur le composé diazo obtenu à l’issue de la réaction de diazotation susmentionnée,
According to one embodiment, the compound of formula (III) is obtained by a diazotization reaction of a compound of formula (IV) below followed by a substitution reaction with a halogen, such as iodine, on the diazo compound obtained at the end of the aforementioned diazotization reaction,
pour obtenir un composé de formule (V) suivante :
et to obtain a compound of the following formula (V): and
- la transformation du composé de formule (V) par borylation de Miyaura pour obtenir un composé de formule (III). - the transformation of the compound of formula (V) by borylation of Miyaura to obtain a compound of formula (III).
Selon un mode de réalisation, le composé de formule (III) est obtenu selon un procédé comprenant les étapes suivantes : According to one embodiment, the compound of formula (III) is obtained according to a process comprising the following steps:
- la réaction du composé de formule (IV) suivante :
avec du nitrite de sodium, notamment en présence de l’APTS mono-hydraté, suivie de l’addition d’iodure de potassium, pour obtenir un composé de formule (V) suivante :
- the reaction of the following compound of formula (IV): with sodium nitrite, in particular in the presence of the monohydrated APTS, followed by the addition of potassium iodide, to obtain a compound of formula (V) below:
- la transformation du composé de formule (V) par borylation de Miyaura pour obtenir un composé de formule (III).
L’étape de réaction de diazotation susmentionnée est effectué dans un solvant adapté pour cette réaction. A titre d’exemple, on peut citer le toluène, le dioxane, en présence ou non d’éthanol et d’eau. - the transformation of the compound of formula (V) by borylation of Miyaura to obtain a compound of formula (III). The aforementioned diazotization reaction step is carried out in a solvent suitable for this reaction. By way of example, mention may be made of toluene, dioxane, in the presence or absence of ethanol and water.
L’étape de réaction susmentionnée est effectuée de préférence dans de l’acétonitrile, en particulier à température ambiante. The above reaction step is preferably carried out in acetonitrile, especially at room temperature.
De préférence, cette étape de réaction est effectuée pendant 4 heures. Preferably, this reaction step is carried out for 4 hours.
L’étape de transformation du composé de formule (V) est effectuée de préférence en présence d’acétate de potassium dans des solvants de type amide, comme par exemple le DMA ou le DMF, et préférentiellement le DMF. The stage of transformation of the compound of formula (V) is preferably carried out in the presence of potassium acetate in solvents of the amide type, such as for example DMA or DMF, and preferentially DMF.
L’étape de réaction susmentionnée est effectuée de préférence à une température comprise de 80°C à 1 10°C, de préférence égale à 90°C, jusqu’à disparition du produit de départ, et notamment pendant 1 heure. The abovementioned reaction step is preferably carried out at a temperature of 80° C. to 110° C., preferably equal to 90° C., until the starting material has disappeared, and in particular for 1 hour.
La présente invention concerne également le composé de formule (II) suivante :
The present invention also relates to the compound of formula (II) below:
Le composé de formule (II) selon l’invention est un composé radiomarqué et correspond à l’énantiomère radiomarqué (S, S) du 5-fluoro-3-4(-phénylpipéridin-1 -yl)- 1 ,2,3,4-tétrahydronaphthalèn-2-ol (FBVM). The compound of formula (II) according to the invention is a radiolabeled compound and corresponds to the radiolabeled (S,S) enantiomer of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3, 4-tetrahydronaphthalen-2-ol (FBVM).
Ce composé est également nommé (+)-(S,S)-5-[18F]-FBVM. This compound is also called (+)-(S,S)-5-[18F] -FBVM .
Ce composé peut être obtenu selon le procédé décrit plus haut pour le composé de formule (I).
La présente invention concerne également le composé répondant à la formuleThis compound can be obtained according to the process described above for the compound of formula (I). The present invention also relates to the compound corresponding to the formula
(III) suivante :
(III) following:
EXEMPLES EXAMPLES
Synthèse des composés rac (+/-)-5-FBVM trans, (ff,ff)-(-)-5-FBVM et (S,S)- (+)-5-FBVM et détermination de leur stéréochimie absolue Synthesis of the compounds rac (+/-)-5-FBVM trans, (ff,ff)-(-)-5-FBVM and (S,S)-(+)-5-FBVM and determination of their absolute stereochemistry
Le rac +/- 5-FBVM a été synthétisé en suivant la voie de synthèse décrite sur les schémas 1 et 2. Le 1 -aminonaphtalène 1 est réduit en 5,8-dihydronaphtalène 2 en utilisant les conditions de Birch puis la fonction amine est protégée avec l’anhydride trifluoroacétique en présence de la triéthylamine pour conduire au composé 3 avec un rendement de 89%. Ce dernier est ensuite engagé dans une réaction d’époxydation pour donner le composé 4 avec un rendement de 85%.The rac +/- 5-FBVM was synthesized following the synthetic route described in schemes 1 and 2. 1-aminonaphthalene 1 is reduced to 5,8-dihydronaphthalene 2 using Birch conditions then the amine function is protected with trifluoroacetic anhydride in the presence of triethylamine to lead to compound 3 with a yield of 89%. The latter is then engaged in an epoxidation reaction to give compound 4 with a yield of 85%.
L’ouverture de l’époxyde en présence par la 4-phenylpipéridine commerciale et la triéthylamine dans le reflux de l’éthanol puis la déprotection de la fonction amine en milieu basique conduit aux deux régioisomères 5-R1 trans et 5-R2 trans avec un rendement global de 60%. Les deux régioisomères 5-R1 trans et 5-R2 trans ont été séparés puis caractérisés.
The opening of the epoxide in the presence by commercial 4-phenylpiperidine and triethylamine in the reflux of ethanol then the deprotection of the amine function in a basic medium leads to the two regioisomers 5-R1 trans and 5-R2 trans with a overall yield of 60%. The two regioisomers 5-R1 trans and 5-R2 trans have been separated and then characterized.
Schéma 1 : Synthèse du précurseur du (rac)- +/- 5-FBVM trans Scheme 1: Synthesis of the precursor of (rac)- +/- 5-FBVM trans
• 5,8-Dihydronaphthalen-1 -amine (2) • 5,8-Dihydronaphthalen-1 -amine (2)
Dans un ballon à fond rond, le composé 1 (16,0 g, 1 12 mmol) a été solubilisé dans du THF anhydre (180 mL) sous atmosphère d'argon, puis du sodium (6,4 g, 279 mmol, 2,5 équivalents) a été ajouté par portions pendant 15 minutes. Après agitation à température ambiante pendant 10 min, une solution de tert-BuOH (26,8 ml, 279 mmol, 2,5 équiv.) dans du THF anhydre (70 mL) a été ajoutée goutte à goutte pendant 30 min (réaction exothermique). La réaction a été laissée sous agitation à la température ambiante pendant 4h. Le mélange réactionnel a été filtré sous vide afin de recueillir le sodium n'ayant pas réagi pour le détruire dans de l'isopropanol à 0°C. Le filtrat a ensuite été concentré pour sécher sous pression réduite. Le brut résiduel a été dissous dans de l'EtsO (120 mL) à 0°C, puis de l'eau (120 mL) a été ajoutée
lentement. Le mélange a été transféré dans une ampoule à décanter, puis la phase organique a été séparée. La phase aqueuse a été extraite avec de l'EtsO (3 x 10 mL) puis les phases organiques ont été combinées, séchées sur du MgSC , filtrées et concentrées pour sous pression réduite. Le brut résiduel a été purifié par chromatographie flash sur colonne de gel de silice (EP/AcOEt : 95/5) pour obtenir le produit 2 souhaité sous forme de sirop brun foncé (13,8 g, 85%). Mp : 236-237°CIn a round-bottomed flask, compound 1 (16.0 g, 112 mmol) was dissolved in anhydrous THF (180 mL) under an argon atmosphere, then sodium (6.4 g, 279 mmol, 2 .5 equivalents) was added in portions over 15 minutes. After stirring at room temperature for 10 min, a solution of tert-BuOH (26.8 mL, 279 mmol, 2.5 equiv.) in anhydrous THF (70 mL) was added dropwise over 30 min (exothermic reaction ). The reaction was left stirring at room temperature for 4h. The reaction mixture was vacuum filtered to collect unreacted sodium for destruction in isopropanol at 0°C. The filtrate was then concentrated to dry under reduced pressure. The residual crude was dissolved in EtsO (120 mL) at 0°C, then water (120 mL) was added slowly. The mixture was transferred to a separatory funnel, then the organic phase was separated. The aqueous phase was extracted with EtsO (3 x 10 mL) then the organic phases were combined, dried over MgSC, filtered and concentrated under reduced pressure. The residual crude was purified by flash chromatography on a column of silica gel (EP/AcOEt: 95/5) to obtain the desired product 2 in the form of a dark brown syrup (13.8 g, 85%). MP: 236-237°C
IR: 3441 , 3372, 3024, 2903, 2841 , 2815, 2607, 2591 , 1584, 1584, 1567, 1536, 1465, 1430, 1343, 1301 , 1246, 1 141 , 1068, 1005, 769, 700, 668.1H NMR (400 MHz, DMSO-c/6) 5 10.32 (brs, 2H, NH2), 7.34 (d, J = 7.7 Hz, 1 H, H-Ar), 7.24 (t, J = 7.7 Hz, 1 H, H-Ar), 7.16 (d, J = 7.7 Hz, 1 H, H-Ar), 5.88 (s, 2H, 2 =CH), 3.53 - 3.32 (m, 4H, 2 CH2).13C NMR (101 MHz, DMSO-c/6) 5 135.6 (Cq), 130.3 (Cq), 128.2 (CH), 128.1 (Cq), 126.7 (CH), 124.0 (CH), 122.9 (CH), 120.9 (CH), 28.8 (CH2), 24.6 (CH2). IR: 3441, 3372, 3024, 2903, 2841, 2815, 2607, 2591, 1584, 1584, 1567, 1536, 1465, 1430, 1343, 1301, 1246, 1141, 1068, 6,70,8 . H NMR (400 MHz, DMSO-c/6) 5 10.32 (brs, 2H, NH 2 ), 7.34 (d, J = 7.7 Hz, 1 H, H-Ar), 7.24 (t, J = 7.7 Hz, 1 H, H-Ar), 7.16 (d, J = 7.7 Hz, 1 H, H-Ar), 5.88 (s, 2H, 2 =CH), 3.53 - 3.32 (m, 4H, 2 CH 2 ). 13 C NMR (101 MHz, DMSO-c/6) 5 135.6 (Cq), 130.3 (Cq), 128.2 (CH), 128.1 (Cq), 126.7 (CH), 124.0 (CH), 122.9 (CH), 120.9 (CH), 28.8 (CH 2 ), 24.6 (CH 2 ).
• /V-(5,8-Dihydronaphthalen-1 -yl)-2,2,2-trifluoroacetamide (3)
• /V-(5,8-Dihydronaphthalen-1-yl)-2,2,2-trifluoroacetamide (3)
3 3
Dans un ballon à fond rond, le composé 2 (13,0 g, 89,7 mmol) a été solubilisé dans du DCM (500 mL). On a ajouté de l'EtsN (25,0 ml, 179,4 mmol, 2.0 équivalents), puis le mélange réactionnel a été refroidi à 0°C. L'anhydride trifluoroacétique (17,6 ml, 134,6 mmol, 1 ,5 équiv.) a été ajouté goutte à goutte et le mélange réactionnel a été laissé sous agitation à 0°C pendant 2h. La réaction a été arrêtée par une lente addition d'eau (250 mL). Le mélange a été transféré dans une ampoule à décanter puis la couche organique a été séparée et lavée avec de la saumure (100 mL) puis une solution saturée de NaHCOs (100 mL), séchée sur MgSO4, filtrée et concentrée pour séchage sous pression réduite. Le brut a été purifié par chromatographie flash sur colonne de gel de silice en utilisant EP/AcOEt (80/20) comme éluant pour obtenir le produit souhaité 3 sous forme de solide rose (19,3 g, 89 %). In a round bottom flask, Compound 2 (13.0 g, 89.7 mmol) was solubilized in DCM (500 mL). EtsN (25.0 mL, 179.4 mmol, 2.0 equiv) was added, then the reaction mixture was cooled to 0°C. Trifluoroacetic anhydride (17.6 ml, 134.6 mmol, 1.5 equiv.) was added dropwise and the reaction mixture was left under stirring at 0° C. for 2 h. The reaction was stopped by a slow addition of water (250 mL). The mixture was transferred to a separating funnel then the organic layer was separated and washed with brine (100 mL) then a saturated solution of NaHCOs (100 mL), dried over MgSO4, filtered and concentrated for drying under reduced pressure . The crude was purified by flash column chromatography on silica gel using EP/AcOEt (80/20) as eluent to obtain the desired product 3 as a pink solid (19.3 g, 89%).
IR: 3277, 3034, 2930, 2900, 2815, 1703, 1610, 1586, 1550, 1467, 1347, 1291 , 1256, 1 185, 1 151 , 1068, 915, 782, 767, 700. 1H NMR (250 MHz, CDCI3) 5 7.69 (brs, 1 H, NH), 7.59 (dd, J = 8.2, 1.3 Hz, 1 H, H-Ar), 7.21 (d, J = 7.9 Hz, 1 H, H-Ar), 7.10 - 7.04 (m, 1 H, H-Ar), 5.90 (ddddt, J = 13.5, 12.0, 8.2, 3.4, 1.7 Hz, 2H, 2 =CH), 3.49 - 3.38 (m, 2H, CH2), 3.23 (tt, J = 6.5, 2.4 Hz, 2H, CH2). 13C NMR (63 MHz, CDCI3) 5 155.2 (q, J= 36.8 Hz, Cq), 135.7 (Cq), 132.1 (Cq), 127.7(CH), 126.9 (Cq), 126.9(CH),
116.1 (q, J = 288.9 Hz, CF3), 29.8 (CH2), 25.2 (CH2). 19F NMR (235 MHz, CDCI3) 5 - 75.58 (d, J = 1.3 Hz). IR: 3277, 3034, 2930, 2900, 2815, 1703, 1610, 1586, 1550, 1467, 1347, 1291, 1256, 1185, 1151, 1068, 915, 782, 767, 700. 250MHz NMR , CDCI 3 ) 5 7.69 (brs, 1 H, NH), 7.59 (dd, J = 8.2, 1.3 Hz, 1 H, H-Ar), 7.21 (d, J = 7.9 Hz, 1 H, H-Ar) , 7.10 - 7.04 (m, 1H, H-Ar), 5.90 (ddddt, J = 13.5, 12.0, 8.2, 3.4, 1.7 Hz, 2H, 2 =CH), 3.49 - 3.38 (m, 2H, CH 2 ) , 3.23 (tt, J = 6.5, 2.4 Hz, 2H, CH 2 ). 13 C NMR (63 MHz, CDCI 3 ) 5 155.2 (q, J= 36.8 Hz, Cq), 135.7 (Cq), 132.1 (Cq), 127.7(CH), 126.9 (Cq), 126.9(CH), 116.1 (q, J = 288.9 Hz, CF 3 ), 29.8 (CH 2 ), 25.2 (CH 2 ). 19 F NMR (235 MHz, CDCI 3 ) 5 - 75.58 (d, J = 1.3 Hz).
• 2,2,2-Trifluoro-/V-(1 a,2,7,7a-tetrahvdronaphtho[2,3-bloxiren-3-yl)acetamide• 2,2,2-Trifluoro-/V-(1a,2,7,7a-tetrahvdronaphtho[2,3-bloxiren-3-yl)acetamide
Hl
hi
Dans un ballon à fond rond, le composé 3 (10,0 g, 41 ,5 mmol) a été solubilisé dans du DCM (80 mL) et de l'Et2O (20 mL) sous atmosphère d'argon. Le mélange a été refroidi à 0°C, puis du mCPBA (8,585 g, 49,8 mmol, 1 ,2 équivalents) a été ajouté en une seule fois. Le mélange réactionnel est agité à température ambiante pendant 20h. La réaction a été arrêtée par l'ajout d'une solution aqueuse saturée de NaHCO3 (60 mL). Les phases organiques et aqueuses ont été séparées et la phase aqueuse a été extraite par du DCM (3 x 60 mL). Les phases organiques ont ensuite été combinées, séchées sur du MgSC et filtrées. Après avoir éliminé les substances volatiles sous pression réduite, le brut résultant a été solubilisé dans une quantité minimale de DCM. L'ajout d'Et2O a permis de former un solide blanc qui a ensuite été recueilli par filtration, lavé avec de l'Et2O et séché sous vide pour obtenir l'époxyde 4 souhaité sous forme de solide blanc (8,4 g, 79 %). In a round bottom flask, compound 3 (10.0 g, 41.5 mmol) was dissolved in DCM (80 mL) and Et 2 O (20 mL) under an argon atmosphere. The mixture was cooled to 0° C., then mCPBA (8.585 g, 49.8 mmol, 1.2 equivalents) was added all at once. The reaction mixture is stirred at ambient temperature for 20 h. The reaction was stopped by adding a saturated aqueous solution of NaHCO 3 (60 mL). The organic and aqueous phases were separated and the aqueous phase was extracted with DCM (3 x 60 mL). The organic phases were then combined, dried over MgSC and filtered. After removing volatiles under reduced pressure, the resulting crude was solubilized in a minimal amount of DCM. Addition of Et 2 O formed a white solid which was then collected by filtration, washed with Et 2 O and dried under vacuum to obtain the desired epoxide 4 as a white solid (8. 4g, 79%).
Mp : 102-103°C. IR : 3241 , 3143, 3067, 3020, 2918, 2899, 2824, 1723, 1608, 1587, 1545, 1471 , 1454, 1423, 1334, 1266, 1155, 1069, 998, 982, 922, 890, 860, 821 , 787, 764, 741.1H NMR (400 MHz, CDCI3) 5 8.15 (brs, 1 H, NH), 7.28 - 7.15 (m, 2H, 2 H-Ar), 7.05 (d, J = 7.3 Hz, 1 H, H-Ar), 3.57 - 3.49 (m, 2H, CH2), 3.44 - 3.18 (m, 2H, CH2), 2.93 (m, 2H, 2 CH).13C NMR (101 MHz, CDCI3) 5 155.4 (q, J = 37.1 Hz, Cq), 133.2 (Cq), 132.4 (Cq), 129.2 (CH), 127.2 (CH), 126.8 (Cq), 123.6 (CH), 1 16.1 (q, J = 288.9 Hz, CF3), 52.3 (CH), 51.5 (CH), 30.1 (CH2), 25.1 (CH2). Mp: 102-103°C. IR: 3241, 3143, 3067, 3020, 2918, 2899, 2824, 1723, 1608, 1587, 1545, 1471, 1454, 1423, 1334, 1266, 1155, 1069, 998, 9826, 902,8 8, 92,8 787, 764, 741. 1 H NMR (400 MHz, CDCI 3 ) 5 8.15 (brs, 1 H, NH), 7.28 - 7.15 (m, 2H, 2 H-Ar), 7.05 (d, J = 7.3 Hz, 1 H, H-Ar), 3.57 - 3.49 (m, 2H, CH 2 ), 3.44 - 3.18 (m, 2H, CH 2 ), 2.93 (m, 2H, 2 CH). 13 C NMR (101 MHz, CDCI 3 ) 5 155.4 (q, J = 37.1 Hz, Cq), 133.2 (Cq), 132.4 (Cq), 129.2 (CH), 127.2 (CH), 126.8 (Cq), 123.6 ( CH), 1 16.1 (q, J = 288.9 Hz, CF 3 ), 52.3 (CH), 51.5 (CH), 30.1 (CH 2 ), 25.1 (CH 2 ).
• Synthèse des composés 5-R1 et 5-R2 : • Synthesis of compounds 5-R1 and 5-R2:
Dans un flacon à fond rond, l'époxyde 4 (3,282 g, 12,8 mmol) a été solubilisé dans de l'EtOH (80 mL) sous argon. La 4-phénylpipéridine (2,059 g, 12,8 mmol, 1.0 équivalent) et la triéthylamine (3,558 ml, 25,5 mmol, 2.0 équivalents) ont été ajoutées puis le mélange réactionnel a été mis au reflux pendant 48 heures. L'EtOH a été
éliminé sous pression réduite puis le brut résultant a été solubilisé dans du MeOH (70 mL). Une solution aqueuse de NaOH (6,128 g dans 50 ml d'eau, 12.0 équivalents) a été ajoutée et le mélange réactionnel a été laissé sous agitation à température ambiante pendant 20h. À la fin de la réaction, un précipité brun s'est formé. Celui-ci a ensuite été recueilli par filtration puis solubilisé dans du DCM pour être purifié par chromatographie flash sur colonne de gel de silice en utilisant du DCM/MeOH (100/0 à 99,5/ 0,5 puis 99/1 à 95/5) comme phase mobile pour obtenir les produits souhaités 5-R1 (1 ,249 g, 31 %) et 5-R2 (1 ,189 g, 29%) comme solides beiges. In a round bottom flask, epoxide 4 (3.282 g, 12.8 mmol) was solubilized in EtOH (80 mL) under argon. 4-Phenylpiperidine (2.059 g, 12.8 mmol, 1.0 equivalent) and triethylamine (3.558 ml, 25.5 mmol, 2.0 equivalent) were added then the reaction mixture was refluxed for 48 hours. EtOH was removed under reduced pressure then the resulting crude was dissolved in MeOH (70 mL). An aqueous solution of NaOH (6.128 g in 50 ml of water, 12.0 equivalents) was added and the reaction mixture was left under stirring at room temperature for 20 h. At the end of the reaction, a brown precipitate formed. This was then collected by filtration and then dissolved in DCM to be purified by flash chromatography on a column of silica gel using DCM/MeOH (100/0 to 99.5/0.5 then 99/1 to 95 /5) as the mobile phase to obtain the desired products 5-R1 (1.249 g, 31%) and 5-R2 (1.189 g, 29%) as beige solids.
• 5-Amino-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4-tetrahydronaphthalen-2-ol (5- R1): • 5-Amino-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol (5-R1):
Mp : 165-166°C. IR : 3453, 3372, 3061 , 3023, 3005, 2929, 2903, 2846, 2846, 2814, 1618, 1586, 1494, 1466, 1439, 1409, 1374, 1331 , 1300, 1250, 1141 , 1068, 1005, 783, 765. HRMS (ESI+) : cale, pour C2I H27N2O [M+H]+: 323.21179 trouvé : 323.21168. 1H NMR (400 MHz, CDCI3) 5 7.36 - 7.29 (m, 2H, H-Ar), 7.28 - 7.19 (m, 3H, 3H-Ar), 6.99 (t, J = 7.7 Hz, 1 H, H-Ar), 6.65 - 6.50 (m, 2H, 2 H-Ar), 4.19 (brs, 1 H, OH), 3.87 (td, J = 10.5, 5.5 Hz, 1 H, CH), 3.60 (brs, 2H, NH2), 3.25 (dd, J = 15.9, 5.5 Hz, 1 H, H de CH2), 2.99 (dt, J = 11 .2, 3.4 Hz, 1 H, H of CH2), 2.93 - 2.76 (m, 4H, CH and H of 2 CH2 et CH2), 2.71 (dd, J= 15.5, 5.6 Hz, 1 H, H of CH2), 2.62 - 2.40 (m, 3H, 2 H of 2 CH2 et CH), 1 .99 - 1 .82 (m, 3H, CH2 et 1 H of CH2), 1 .76 (qd, J = 12.4, 3.8 Hz, 1 H, H de CH2).13C NMR (101 MHz, CDCI3) 5 146.2 (Cq), 144.6 (Cq), 135.1 (Cq), 128.6 (2CH), 127.1 (CH), 127.0 (2CH), 126.4 (CH), 1 19.9 (CH), 119.9 (Cq), 1 12.8 (CH), 66.8 (CH), 65.4 (CH), 53.69 (CH2), 45.1 (CH2), 43.1 (CH), 38.3 (CH2), 34.5 (CH2), 34.0 (CH2), 21 .0 (CH2). 19F NMR (376 MHz, CDCI3) 5 -75.3. Mp: 165-166°C. IR: 3453, 3372, 3061, 3023, 3005, 2929, 2903, 2846, 2846, 2814, 1618, 1586, 1494, 1466, 1439, 1409, 1374, 1331, 1300, 1265, 7, 8, 1038 765. HRMS (ESI + ): wedge, for C 2 IH 27 N 2 O [M+H] + : 323.21179 found: 323.21168. 1 H NMR (400 MHz, CDCI 3 ) 5 7.36 - 7.29 (m, 2H, H-Ar), 7.28 - 7.19 (m, 3H, 3H-Ar), 6.99 (t, J = 7.7 Hz, 1 H, H -Ar), 6.65 - 6.50 (m, 2H, 2H-Ar), 4.19 (brs, 1H, OH), 3.87 (td, J = 10.5, 5.5 Hz, 1H, CH), 3.60 (brs, 2H , NH 2 ), 3.25 (dd, J = 15.9, 5.5 Hz, 1 H, H of CH 2 ), 2.99 (dt, J = 11.2, 3.4 Hz, 1 H, H of CH 2 ), 2.93 - 2.76 (m, 4H, CH and H of 2 CH 2 and CH 2 ), 2.71 (dd, J= 15.5, 5.6 Hz, 1 H, H of CH 2 ), 2.62 - 2.40 (m, 3H, 2 H of 2 CH 2 and CH), 1.99 - 1.82 (m, 3H, CH 2 and 1 H of CH 2 ), 1.76 (qd, J = 12.4, 3.8 Hz, 1 H, H of CH 2 ). 13 C NMR (101 MHz, CDCI 3 ) 5 146.2 (Cq), 144.6 (Cq), 135.1 (Cq), 128.6 (2CH), 127.1 (CH), 127.0 (2CH), 126.4 (CH), 1 19.9 (CH ), 119.9 (Cq), 1 12.8 (CH), 66.8 (CH), 65.4 (CH), 53.69 (CH 2 ), 45.1 (CH 2 ), 43.1 (CH), 38.3 (CH 2 ), 34.5 (CH 2 ), 34.0 (CH 2 ), 21 .0 (CH 2 ). 19 F NMR (376 MHz, CDCI3) 5 -75.3.
• 8-Amino-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4-tetrahvdronaphthalen-2-ol• 8-Amino-3-(4-phenylpiperidin-1 -yl)-1,2,3,4-tetrahvdronaphthalen-2-ol
(5-R2) : (5-R2):
Mp : 210-211 °C. IR : 3441 , 3374, 3067, 3023, 2929, 2904, 2846, 2813, 1618, 1587, 1494, 1466, 1439, 1410, 1375, 1331 , 1299, 1250, 1 129, 1068, 1005, 983, 783, 765, 700. HRMS (ESI+) : cale, pour C2I H27N2O [M+H]+: 323.21 179 trouvé : 323.21 146. 1H NMR (400 MHz, CDCI3) 5 7.33 (t, J = 7.5 Hz, 2H, 2H-Ar), 7.28 - 7.19 (m, 3H, 3H- Ar), 6.98 (t, J = 7.7 Hz, 1 H, H-Ar), 6.56 (t, J = 7.2 Hz, 2H, H-Ar), 4.34 (brs, 1 H, OH), 3.93 (td, J = 9.8, 6.1 Hz, 1 H, CH), 3.62 (brs, 2H, NH2), 3.13 (dd, J = 15.6, 6.3 Hz, 1 H, 1 H of CH2), 3.00 (d, J = 11 .2 Hz, 1 H, CH2), 2.93 - 2.73 (m, 5H, CH et 2 CH2), 2.57 (tt, J= 12.0, 4.1 Hz, 1 H, CH), 2.47 - 2.32 (m, 2H, 2 H de 2 CH2), 1.98 - 1.82 (m, 3H, CH2
et H de CH2), 1 .75 (qd, J = 12.3, 3.8 Hz, 1 H, 1 H de CH2).13C NMR (101 MHz, CDCI3) 5 146.2 (Cq), 144.6 (Cq), 136.1 (Cq), 128.6(2CH), 127.0 (CH), 127.0 (2CH), 126.4 (CH), 1 19.5 (CH), 1 18.9 (Cq), 112.7 (CH), 66.2 (CH), 66.1 (CH), 53.8 (CH2), 45.2 (CH2), 43.1 (CH), 34.4 (CH2), 34.0 (CH2), 33.3 (CH2), 26.6 (CH2). Mp: 210-211°C. IR: 3441, 3374, 3067, 3023, 2929, 2904, 2846, 2813, 1618, 1587, 1494, 1466, 1439, 1410, 1375, 1331, 1299, 1250, 1129, 103, 7, 8, 8 , 700. HRMS (ESI + ): wedge, for C 2 IH 27 N 2 O [M+H] + : 323.21 179 found: 323.21 146. 1 H NMR (400 MHz, CDCI3) 5 7.33 (t, J = 7.5 Hz, 2H, 2H-Ar), 7.28 - 7.19 (m, 3H, 3H-Ar), 6.98 (t, J = 7.7 Hz, 1H, H-Ar), 6.56 (t, J = 7.2 Hz, 2H, H-Ar), 4.34 (brs, 1H, OH), 3.93 (td, J = 9.8, 6.1 Hz, 1H, CH), 3.62 (brs, 2H, NH 2 ), 3.13 (dd, J = 15.6, 6.3 Hz, 1 H, 1 H of CH 2 ), 3.00 (d, J = 11 .2 Hz, 1 H, CH 2 ), 2.93 - 2.73 (m, 5H, CH and 2 CH 2 ), 2.57 (tt, J= 12.0, 4.1 Hz, 1 H, CH), 2.47 - 2.32 (m, 2H, 2 H of 2 CH 2 ), 1.98 - 1.82 (m, 3H, CH 2 and H of CH 2 ), 1.75 (qd, J = 12.3, 3.8 Hz, 1 H, 1 H of CH 2 ). 13 C NMR (101 MHz, CDCI 3 ) 5 146.2 (Cq), 144.6 (Cq), 136.1 (Cq), 128.6(2CH), 127.0 (CH), 127.0 (2CH), 126.4 (CH), 1 19.5 (CH ), 1 18.9 (Cq), 112.7 (CH), 66.2 (CH), 66.1 (CH), 53.8 (CH 2 ), 45.2 (CH 2 ), 43.1 (CH), 34.4 (CH 2 ), 34.0 (CH 2 ), 33.3 (CH 2 ), 26.6 (CH 2 ).
Le régioisomère d’intérêt 5-R1 trans a été ensuite engagé dans une réaction de Balz-Schiemann pour donner le produit rac 5-FBVM Trans avec un rendement de 59%. Afin de séparer les deux énantiomères du (rac)- (+/ -5-FBVM Trans, ce dernier a été transformé en ester de Mosher par le biais de (R)-(+)-acide a-méthoxy- a-trifluorométhylphénylacétique commercial utilisé comme copule chirale. En utilisant les conditions de Steglich, les deux diastéréoisomères 6-D1 et 6-D2 ont été obtenus et séparés avec un rendement global de 60%.
The 5-R1 trans regioisomer of interest was then engaged in a Balz-Schiemann reaction to give the rac product 5-FBVM Trans with a yield of 59%. In order to separate the two enantiomers of (rac)-(+/-5-FBVM Trans, the latter was transformed into a Mosher ester through commercial (R)-(+)-a-methoxy-a-trifluoromethylphenylacetic acid used as a chiral copula Using the Steglich conditions, the two diastereoisomers 6-D1 and 6-D 2 were obtained and separated with an overall yield of 60%.
Schéma 2 : Synthèse de l’ester de Mosher et séparation des diastéréoisomères. Plaque CCM montrant la séparation de ces produits. Scheme 2: Synthesis of the Mosher ester and separation of the diastereoisomers. TLC plate showing the separation of these products.
• 5-Fluoro-3-(4-DhenylDiDeridin-1 -yl)-1 ,2,3,4-tetrahvdronaDhthalen-2-ol ((rac)- (+/-1-5-FBVM) : • 5-Fluoro-3-(4-DhenylDiDeridin-1-yl)-1,2,3,4-tetrahvdronaDhthalen-2-ol ((rac)- (+/-1-5-FBVM):
Dans un réacteur tubulaire séché au four équipé d'un agitateur et d'un bouchon à vis en téflon, le composé 5-R1 (849 mg, 2,6 mmol), le BF3.Et2O (818 pl, 6,6 mmol, 2,5 équivalents) et le 1 ,2-dichlorobenzène (9 mL) ont été ajoutés. Le mélange a été refroidi à 0°C, puis du tert-BuONO (629 pl, 4,7 mmol, 1 ,8 équiv.) a été ajouté à l'aide d'une seringue sous atmosphère d'argon et à 0°C. Le mélange a été agité à 0°C pendant 15 min puis une solution de PIDA (170 mg, 0,5 mmol, 0,2 équiv.) dans du 1 ,2-dichlorobenzène (2 mL) a été ajoutée. Le réacteur a été scellé et chauffé à 40°C pendant 36h. Après refroidissement, le mélange a été évaporé sous vide. Le brut a été solubilisé dans du DCM (30 mL) et lavé avec une solution aqueuse saturée de NaHCOs (30 mL) séchée sur du MgSC , puis filtré sous pression réduite. Le brut obtenu a été purifié par chromatographie flash en utilisant EP/AcOEt (10/0 à 1/1 )
comme éluant pour obtenir le (rac)-5-FBVM (500 mg, 59%) souhaité sous forme de solide beige pâle. Mp : 147-148°C. In an oven-dried tubular reactor equipped with a stirrer and a Teflon screw cap, Compound 5-R1 (849 mg, 2.6 mmol), BF3.Et 2 O (818 µl, 6.6 mmol, 2.5 equivalents) and 1,2-dichlorobenzene (9 mL) were added. The mixture was cooled to 0°C, then tert-BuONO (629 µl, 4.7 mmol, 1.8 equiv.) was added using a syringe under an argon atmosphere and at 0° vs. The mixture was stirred at 0°C for 15 min then a solution of PIDA (170 mg, 0.5 mmol, 0.2 equiv.) in 1,2-dichlorobenzene (2 mL) was added. The reactor was sealed and heated at 40°C for 36 h. After cooling, the mixture was evaporated under vacuum. The crude was dissolved in DCM (30 mL) and washed with a saturated aqueous solution of NaHCOs (30 mL) dried over MgSC, then filtered under reduced pressure. The crude obtained was purified by flash chromatography using EP/AcOEt (10/0 to 1/1) as eluant to obtain the desired (rac)-5-FBVM (500 mg, 59%) as a pale beige solid. Mp: 147-148°C.
IR (v cm-1) : 3434, 3079, 3048, 3025, 2931 , 2910, 2870, 2840, 2813, 1579, 1492, 1462, 141 1 , 1376, 1278, 1238, 1 141 , 1 124, 1072, 1003, 981 , 782, 769, 711 , 696. HRMS (ESI+) : cale, pour C2I H25FNO [M+H]+: 326. 19146 trouvé : 326.19131 . 1H NMR (250 MHz, CDCI3) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H, 2 H-Ar), 4.34 (brs, 1 H, OH), 3.87 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.33 (dd, J = 16.2, 5.7 Hz, 1 H, H de CH2), 3.15 - 3.02 (m, 1 H, H de CH2), 3.02 - 2.84 (m, 3H, CH de CH2 et CH2), 2.83 - 2.50 (m, 4H, 2H de CH2 et 2 CH), 2.44 (td, J= 11 .5, 2.5 Hz, 1 H, H de CH2), 2.01 - 1 .86 (m, 3H, CH et H de CH2), 1 .85 - 1 .62 (m, 1 H, H de CH2). 13C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2(Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7 Hz, CH), 127.0(2CH), 126.4 (CH), 124.7 (d, J = 3.3 Hz, CH), 122.7 (d, J = 17.6 Hz, Cq), 1 12.4 (d, J = 21.9 Hz, CH), 66.2 (CH), 65.4(CH), 53.8(CH2), 45.1 (CH2), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH2), 34.5 (CH2), 34.0 (CH2), 19.2 (d, J = 3.3 Hz, CH2). 19F NMR (235 MHz, CDCI3) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz). IR (v cm-1): 3434, 3079, 3048, 3025, 2931, 2910, 2870, 2840, 2813, 1579, 1492, 1462, 1411, 1376, 1278, 1238, 1141, 1124, 1073 , 981, 782, 769, 711, 696. HRMS (ESI + ): wedge, for C 2 IH 25 FNO [M+H] + : 326. 19146 found: 326.19131. 1 H NMR (250 MHz, CDCI3) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H , 2 H-Ar), 4.34 (brs, 1 H, OH), 3.87 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.33 (dd, J = 16.2, 5.7 Hz, 1 H, H de CH 2 ), 3.15 - 3.02 (m, 1 H, H of CH 2 ), 3.02 - 2.84 (m, 3H, CH of CH2 and CH2), 2.83 - 2.50 (m, 4H, 2H of CH2 and 2 CH), 2.44 (td, J= 11.5, 2.5 Hz, 1 H, H from CH 2 ), 2.01 - 1.86 (m, 3H, CH and H from CH 2 ), 1.85 - 1.62 (m, 1 H, H of CH 2 ). 13 C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2 (Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7Hz, CH), 127.0(2CH), 126.4(CH), 124.7(d, J=3.3Hz, CH), 122.7(d, J=17.6Hz, Cq), 1 12.4(d, J=21.9Hz, CH), 66.2 (CH), 65.4(CH), 53.8(CH 2 ), 45.1 (CH 2 ), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH 2 ), 34.5 (CH 2 ), 34.0 (CH 2 ), 19.2 (d, J = 3.3 Hz, CH 2 ). 19 F NMR (235 MHz, CDCI3) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz).
• Synthèse des esters de Mosher 6-D1 et 6-D2:
• Synthesis of Mosher esters 6-D1 and 6-D2:
Dans un ballon à fond rond séché au four, le rac-(+/-)-5-FBVM (650 mg, 2.0 mmol) a été solubilisé dans du DCM (5 mL). La DCC (515 mg, 2,5 mmol, 1 ,25 équiv.), le DMAP (5 mg, 0,4 mmol, 0,2 équiv.) et l'acide de Mosher (561 mg, 2,4 mmol, 1 ,2 équiv.) ont été ajoutés respectivement sous atmosphère d'argon. Le mélange réactionnel a été laissé sous agitation à température ambiante pendant 24 heures. La réaction a été arrêtée en ajoutant une solution aqueuse saturée de NaHCOs (30 mL), puis transférée dans une ampoule à décanter. La couche organique a été recueillie et la couche aqueuse a été extraite avec du DCM (2 x 30 mL). Ensuite, les couches organiques ont été combinées ensemble, séchées sur du MgSC et filtrées. Le solvant a été éliminé sous pression réduite. Le brut obtenu a été purifié par chromatographie flash sur colonne de gel de silice en utilisant le mélange EP/AcOEt
(100/0 à 95:5) comme éluant pour obtenir les produits souhaités 6-D1 (276 mg, 26%) et 6-D2 (369 mg, 34%) sous forme de solides amorphes blancs. In an oven-dried round bottom flask, rac-(+/-)-5-FBVM (650 mg, 2.0 mmol) was solubilized in DCM (5 mL). DCC (515 mg, 2.5 mmol, 1.25 equiv.), DMAP (5 mg, 0.4 mmol, 0.2 equiv.) and Mosher's acid (561 mg, 2.4 mmol, 1.2 equiv.) were added respectively under an argon atmosphere. The reaction mixture was left stirring at room temperature for 24 hours. The reaction was stopped by adding a saturated aqueous solution of NaHCOs (30 mL), then transferred to a separatory funnel. The organic layer was collected and the aqueous layer was extracted with DCM (2 x 30 mL). Then the organic layers were combined together, dried over MgSC and filtered. The solvent was removed under reduced pressure. The crude product obtained was purified by flash chromatography on a column of silica gel using the EP/AcOEt mixture (100/0 at 95:5) as eluent to obtain the desired products 6-D1 (276 mg, 26%) and 6-D2 (369 mg, 34%) as white amorphous solids.
(F?)-/, F?,3F?)-5-Fluoro-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4-tetrahydronaphthalen- 2-yl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (6-D1) : (F?)-/ , F?,3F?)-5-Fluoro-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 3,3,3-trifluoro -2-methoxy-2-phenylpropanoate (6-D1):
HRMS (ESI+) : cale, pour C31H32F4NO3 [M+H]+: 542.23128 trouvé : 542.23097. IR (v ern 1): 3060.5, 3002.6, 2975.1 , 2947.0, 2889.8, 2850.1 , 2353.1 , 1738.2, 1588.1 ,HRMS (ESI + ): wedge, for C31H32F4NO3 [M+H] + : 542.23128 found: 542.23097. IR (ver 1 ): 3060.5, 3002.6, 2975.1, 2947.0, 2889.8, 2850.1, 2353.1, 1738.2, 1588.1,
1496.7, 1474.7, 1452.4, 1405.2, 1384.4, 1258.2, 1 197.8, 1187.1 , 1 170.0, 1 112.5,1496.7, 1474.7, 1452.4, 1405.2, 1384.4, 1258.2, 1197.8, 1187.1, 1170.0, 1112.5,
1079.8, 1054.2, 1015.7, 995.1 , 969.9, 952.5, 88.8, 793.5, 763.0, 745.8, 736.7, 720.8, 704.0, 661 .8. 1H NMR (250 MHz, CDCI3) 5 7.80 (dd, J = 6.5, 3.1 Hz, 2H, 2H-Ar), 7.541079.8, 1054.2, 1015.7, 995.1, 969.9, 952.5, 88.8, 793.5, 763.0, 745.8, 736.7, 720.8, 704.0, 661.8. 1 H NMR (250 MHz, CDCI3) 5 7.80 (dd, J=6.5, 3.1 Hz, 2H, 2H-Ar), 7.54
- 7.44 (m, 3H, 3 H-Ar), 7.41 - 7.31 (m, 2H, 2H-Ar), 7.31 - 7.21 (m, 3H, 3 H-Ar), 7.21- 7.44 (m, 3H, 3H-Ar), 7.41 - 7.31 (m, 2H, 2H-Ar), 7.31 - 7.21 (m, 3H, 3H-Ar), 7.21
- 7.09 (m, 1 H, 1 H-Ar), 7.02 - 6.80 (m, 2H, 2 H-Ar), 5.63 (td, J = 9.5, 5.9 Hz, 1 H, CH), 3.78 (s, 3H, OMe), 3.32 - 3.09 (m, 4H, CH et 3 H de 3CH2), 3.07 - 2.76 (m, 4H,2H of 2CH2 et CH2), 2.64 - 2.40 (m, 2H, CH et 1 H de CH2), 2.02 - 1 .62 (m, 4H, 2 CH2). 13C NMR (63 MHz, CDCI3) 5 166.0 (Cq), 160.7 (d, J = 244.5 Hz, Cq), 146.5 (Cq), 135.7 (d, J = 4.4 Hz, Cq), 132.6 (Cq), 129.8 (CH), 128.6 (4CH), 127.8 (2CH), 127.5 (d, J = 8.6 Hz, CH), 126.9 (2CH), 126.3 (CH), 124.0 (d, J = 3.3 Hz, CH), 123.5 (q, J = 288.9, CF3), 122.5 (d, J = 17.7 Hz, Cq), 1 12.9 (d, J = 21.8 Hz, CH), 85.0 (q, J= 27.4 Hz, Cq), 71.2 (CH), 63.2 (CH), 55.70 (d, J = 1.5 Hz, CH3), 52.8 (CH2), 46.8 (CH2), 42.9 (CH), 34.8 (d, J = 2.1 Hz, CH2), 34.5 (CH2), 33.2 (CH2), 19.9 (d, J = 2.9 Hz, CH2). 19F NMR (235 MHz, CDCI3) 5 -71.1 , -1 17.8 (dd, J = 9.4, 5.7 Hz). - 7.09 (m, 1H, 1H-Ar), 7.02 - 6.80 (m, 2H, 2H-Ar), 5.63 (td, J = 9.5, 5.9 Hz, 1H, CH), 3.78 (s, 3H , OMe), 3.32 - 3.09 (m, 4H, CH and 3 H of 3CH 2 ), 3.07 - 2.76 (m, 4H,2H of 2CH 2 and CH 2 ), 2.64 - 2.40 (m, 2H, CH and 1 H of CH 2 ), 2.02 - 1.62 (m, 4H, 2 CH 2 ). 13 C NMR (63 MHz, CDCI3) 5 166.0 (Cq), 160.7 (d, J = 244.5 Hz, Cq), 146.5 (Cq), 135.7 (d, J = 4.4 Hz, Cq), 132.6 (Cq), 129.8 (CH), 128.6 (4CH), 127.8 (2CH), 127.5 (d, J=8.6Hz, CH), 126.9 (2CH), 126.3 (CH), 124.0 (d, J=3.3Hz, CH), 123.5 ( q, J = 288.9, CF 3 ), 122.5 (d, J = 17.7 Hz, Cq), 1 12.9 (d, J = 21.8 Hz, CH), 85.0 (q, J= 27.4 Hz, Cq), 71.2 (CH ), 63.2 (CH), 55.70 (d, J = 1.5 Hz, CH 3 ), 52.8 (CH 2 ), 46.8 (CH 2 ), 42.9 (CH), 34.8 (d, J = 2.1 Hz, CH 2 ), 34.5 (CH 2 ), 33.2 (CH 2 ), 19.9 (d, J = 2.9 Hz, CH 2 ). 19 F NMR (235 MHz, CDCI 3 ) 5 -71.1 , -1 17.8 (dd, J = 9.4, 5.7 Hz).
• fF?)-/' S,3S)-5-Fluoro-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4- tetrahydronaphthalen-2-yl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (6-D2) : • fF?)-/'S,3S)-5-Fluoro-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 3,3,3-trifluoro-2 -methoxy-2-phenylpropanoate (6-D2):
HRMS (ESI+): cale, pour C3I H32F4NO3 [M+H]+: 542.23128 trouvé : 542.23125. IR (v cm 1): 3025.6, 2978.2, 2943.6, 291 1 .9, 2849.8, 2794.8, 2737.6, 2621 .6, 2603.5,HRMS (ESI + ): wedge, for C 3 IH 32 F 4 NO 3 [M+H] + : 542.23128 found: 542.23125. IR (v cm 1 ): 3025.6, 2978.2, 2943.6, 291 1 .9, 2849.8, 2794.8, 2737.6, 2621 .6, 2603.5,
2497.9, 1746.9, 1619.3, 1584.5, 1493.1 , 1465.6, 1450.7, 1397.5, 1385.3, 1325.9, 1293.4, 1243.5, 1 187.3, 1 166.1 , 1 122.5, 1108.9, 1079.6, 1012.2, 966.5, 786.5, 762.8, 734.5, 719.2, 699.7. 1H NMR (250 MHz, CDCI3) 5 7.74 - 7.61 (m, 2H, 2H-Ar), 7.47 - 7.38 (m, 3H, 3H-Ar), 7.34 - 7.26 (m, 2H, 2H-Ar), 7.23 - 7.06 (m, 4H, 4H-Ar), 6.94 - 6.83 (m, 2H, 2H-Ar), 5.51 (td, J = 8.6, 5.5 Hz, 1 H, CH), 3.63 (q, J= 1.2 Hz, 3H, OMe), 3.34 (dd, J = 16.2, 5.6 Hz, 1 H, H de CH2), 3.15 - 2.73 (m, 6H, CH2, 3H de 3CH2 et CH), 2.51 (td, J = 1 1 .3, 2.7 Hz, 1 H, H de CH2), 2.42 - 2.22 (m, 2H, H of CH2 and CH), 1.67 (dtq, J = 28.9, 12.2, 4.0 Hz, 4H, 2CH2).13C NMR (63 MHz, CDCI3) 5 166.0 (Cq), 160.7 (d, J = 244.8 Hz, Cq), 146.5 (Cq), 135.6 (d, J = 4.4 Hz, Cq), 132.4 (Cq), 129.7 (CH), 128.5 (2CH), 128.5 (2CH), 127.8 (2CH), 127.5 (d, J = 8.6 Hz, CH), 126.9 (2CH),
126.2 (CH), 124.0 (d, J = 3.4 Hz, CH), 123.5 (q, J = 288.6 Hz, CF3), 122.7 (d, J = 17.7 Hz, Cq), 113.0 (d, J = 21 .7 Hz, CH), 84.7 (q, J = 27.5 Hz, Cq), 72.3 (CH), 62.6 (CH2), 55.7 (CH3), 51.3 (CH2), 48.7 (CH2), 42.8 (CH), 34.7 (d, J = 2.2 Hz, CH2), 34.2 (CH), 33.6 (CH2), 21.3 (d, J = 3.1 Hz, CH2).19F NMR (235 MHz, CDCI3) 5 -71.84, -118.06 (dd, J = 9.5, 5.7 Hz). 2497.9, 1746.9, 1619.3, 1584.5, 1493.1, 1465.6, 1450.7, 1397.5, 1385.3, 1325.9, 1293.4, 1243.5, 1 187.3, 1 166.1, 1 122.5, 1108.9, 1079.6, 1012.2, 786. . 1 H NMR (250 MHz, CDCI 3 ) 5 7.74 - 7.61 (m, 2H, 2H-Ar), 7.47 - 7.38 (m, 3H, 3H-Ar), 7.34 - 7.26 (m, 2H, 2H-Ar), 7.23 - 7.06 (m, 4H, 4H-Ar), 6.94 - 6.83 (m, 2H, 2H-Ar), 5.51 (td, J = 8.6, 5.5 Hz, 1 H, CH), 3.63 (q, J= 1.2 Hz, 3H, OMe), 3.34 (dd, J = 16.2, 5.6 Hz, 1 H, H of CH 2 ), 3.15 - 2.73 (m, 6H, CH 2 , 3H of 3CH 2 and CH), 2.51 (td, J = 1 1 .3, 2.7 Hz, 1 H, H of CH 2 ), 2.42 - 2.22 (m, 2H, H of CH 2 and CH), 1.67 (dtq, J = 28.9, 12.2, 4.0 Hz, 4H, 2CH2 ). 13 C NMR (63 MHz, CDCI 3 ) 5 166.0 (Cq), 160.7 (d, J = 244.8 Hz, Cq), 146.5 (Cq), 135.6 (d, J = 4.4 Hz, Cq), 132.4 (Cq), 129.7 (CH), 128.5 (2CH), 128.5 (2CH), 127.8 (2CH), 127.5 (d, J=8.6Hz, CH), 126.9 (2CH), 126.2 (CH), 124.0 (d, J = 3.4 Hz, CH), 123.5 (q, J = 288.6 Hz, CF 3 ), 122.7 (d, J = 17.7 Hz, Cq), 113.0 (d, J = 21 . 7 Hz, CH), 84.7 (q, J = 27.5 Hz, Cq), 72.3 (CH), 62.6 (CH 2 ), 55.7 (CH 3 ), 51.3 (CH 2 ), 48.7 (CH 2 ), 42.8 (CH ), 34.7 (d, J = 2.2 Hz, CH 2 ), 34.2 (CH), 33.6 (CH 2 ), 21.3 (d, J = 3.1 Hz, CH 2 ). 19 F NMR (235 MHz, CDCI 3 ) 5 -71.84, -118.06 (dd, J = 9.5, 5.7 Hz).
• 1-((2F?,3F?)-8-Fluoro-3-(((F?)-3,3,3-thfluoro-2-methoxy-2- phenylpropanoyl)oxy)-1 ,2,3,4-tetrahvdronaphthalen-2-yl)-4-phenylpiperidin-1-ium chloride (6
• 1-((2F?,3F?)-8-Fluoro-3-(((F?)-3,3,3-thfluoro-2-methoxy-2-phenylpropanoyl)oxy)-1,2,3, 4-tetrahvdronaphthalen-2-yl)-4-phenylpiperidin-1-ium chloride (6
Dans un ballon à fond rond, le composé 6-D1 (250 mg, 0,46 mmol) a été solubilisé dans un dioxane (3 ml) puis refroidi à 0°C. Une solution de HCl 4N dans le dioxane (173 pL, 0,69 mmol, 1 ,5 équivalent) a été ajoutée goutte à goutte et laissée sous agitation à t.r. pendant 24 heures. Le solvant et l'excès de HCl ont été éliminés à la pression atmosphérique pour obtenir des cristaux. Le brut était ensuite trituré avec de l'Et2O pour obtenir un solide blanc, qui était recueilli par filtration puis séché sous vide pour obtenir du 6-D1-HCI en rendement quantitatif. Certains cristaux ont été collectés pour l'analyse aux rayons X. Mp : 168-169 °C. IR (v cm'1) : 3028.3,In a round bottom flask, compound 6-D1 (250 mg, 0.46 mmol) was dissolved in dioxane (3 mL) then cooled to 0°C. A solution of 4N HCl in dioxane (173 μL, 0.69 mmol, 1.5 equivalent) was added dropwise and left under stirring at tr for 24 hours. Solvent and excess HCl were removed at atmospheric pressure to obtain crystals. The crude was then triturated with Et 2 O to obtain a white solid, which was collected by filtration and then dried under vacuum to obtain 6-D1-HCI in quantitative yield. Some crystals were collected for X-ray analysis. Mp: 168-169°C. IR (v cm -1 ): 3028.3,
3006.8, 2951.6, 2853.6, 2359.9, 1748.3, 1590.4, 1470.3, 1446.9, 1245.0, 1163.4,3006.8, 2951.6, 2853.6, 2359.9, 1748.3, 1590.4, 1470.3, 1446.9, 1245.0, 1163.4,
1118.8, 1078.9, 1014.8, 963.9, 845.0, 750.2, 721 .3, 700.1 , 664.1 , 552.4. 1H NMR (250 MHz, DMSO-cfe) 5 11.62 (bs, 1 H, NH), 7.48 (s, 5H, 5H-Ar), 7.40 - 7.30 (m, 2H, 2H- Ar), 7.29 - 7.12 (m, 4H, 4 H-Ar), 7.10 - 6.92 (m, 2H, 2H-Ar), 5.95 (d, J = 4.9 Hz, 1 H, CH), 3.99 - 3.83 (m, 1 H, CH), 3.79 - 2.90 (m, 11 H, 4CH2 et OMe), 2.88 - 2.67 (m, 1 H, CH), 2.27 (d, J = 14.0 Hz, 2H, 2H of 2 CH2), 2.07 - 1 .86 (m, 2H, 2H de 2 CH2). 13C NMR (63 MHz, DMSO-cfe) 5 164.7 (Cq), 159.1 (d, J = 244.2 Hz, Cq), 144.1 (Cq), 135.5 (d, J = 2.9 Hz, Cq), 130.7 (Cq), 130.0 (CH), 128.8 (2CH), 128.6 (2CH), 128.2 (d, J = 8.2 Hz, CH), 127.2 (2CH), 126.6 (3CH), 124.2 (CH), 123.1 (q, J = 290.4 Hz, CF3) 119.7 (d, J = 16.5 Hz, Cq), 113.4 (d, J = 20.9 Hz, CH), 84.2 (q, J = 27.2, 26.6 Hz, Cq), 71.9 (CH), 63.14 (CH), 55.6 (CH3), 50,6 (CH2), 49.3 (CH2), 39.2 (CH), 32.6
CH2, 29.8 (CH2), 29.6 (CH2), 20.7 (CH2). 19F NMR (235 MHz, DMSO-cfe) 5 -70.9, -1118.8, 1078.9, 1014.8, 963.9, 845.0, 750.2, 721.3, 700.1, 664.1, 552.4. 1 H NMR (250 MHz, DMSO-cfe) 5 11.62 (bs, 1 H, NH), 7.48 (s, 5H, 5H-Ar), 7.40 - 7.30 (m, 2H, 2H-Ar), 7.29 - 7.12 ( m, 4H, 4H-Ar), 7.10 - 6.92 (m, 2H, 2H-Ar), 5.95 (d, J = 4.9 Hz, 1H, CH), 3.99 - 3.83 (m, 1H, CH), 3.79 - 2.90 (m, 11 H, 4CH 2 and OMe), 2.88 - 2.67 (m, 1 H, CH), 2.27 (d, J = 14.0 Hz, 2H, 2H of 2 CH 2 ), 2.07 - 1.86 (m, 2H, 2H of 2 CH 2 ). 13 C NMR (63 MHz, DMSO-cfe) 5 164.7 (Cq), 159.1 (d, J = 244.2 Hz, Cq), 144.1 (Cq), 135.5 (d, J = 2.9 Hz, Cq), 130.7 (Cq) , 130.0 (CH), 128.8 (2CH), 128.6 (2CH), 128.2 (d, J=8.2Hz, CH), 127.2 (2CH), 126.6 (3CH), 124.2 (CH), 123.1 (q, J=290.4 Hz, CF 3 ) 119.7 (d, J = 16.5 Hz, Cq), 113.4 (d, J = 20.9 Hz, CH), 84.2 (q, J = 27.2, 26.6 Hz, Cq), 71.9 (CH), 63.14 ( CH), 55.6 ( CH3 ), 50.6 ( CH2 ), 49.3 ( CH2 ), 39.2 (CH), 32.6 CH 2 , 29.8 (CH 2 ), 29.6 (CH 2 ), 20.7 (CH 2 ). 19 F NMR (235 MHz, DMSO-cfe) 5 -70.9, -
119.9 (dd, J = 9.1 , 5.8 Hz). 119.9 (dd, J = 9.1, 5.8Hz).
La cristallisation des esters de Mosher 6-D1 et 6-D2 dans divers solvants et combinaison de solvants a échoué. Toutefois, la solubilisation de 6-D1 dans une solution de HCl (4N) dans le dioxane suivi de l’évaporation lente du solvant à température ambiante a permis d’obtenir des cristaux du sel 6-D1 .HCl. L’analyse de ces derniers par diffraction des rayons X a montré que les trois centres asymétriques de 6-D1 possèdent comme stéréochimie absolue (R, R, R). Crystallization of Mosher esters 6-D1 and 6-D 2 in various solvents and combination of solvents failed. However, the solubilization of 6-D1 in a solution of HCl (4N) in dioxane followed by the slow evaporation of the solvent at room temperature made it possible to obtain crystals of the salt 6-D1.HCl. Analysis of the latter by X-ray diffraction showed that the three asymmetric centers of 6-D1 possess as absolute stereochemistry (R, R, R).
Les cristaux ont donc été ensuite engagés dans une réaction d’hydrolyse de l’ester en milieu basique pour donner le (7?,R)-5-FBVM avec un rendement de 80%. Finalement, le (7?,R 5-FBVM a été analysé par polarimétrie afin de déterminer le sens de déviation de la lumière polarisée. Cette analyse a montré un pouvoir rotatoire de [CID]20°C = -82.0° (10 mg dans 1 ml de Chloroforme). Le (-)-(7?,RJ-5-FBVM est donc obtenu (Schéma 3).
The crystals were therefore then engaged in a hydrolysis reaction of the ester in a basic medium to give (7?,R)-5-FBVM with a yield of 80%. Finally, the (7?,R 5-FBVM) was analyzed by polarimetry in order to determine the direction of deflection of the polarized light. This analysis showed an optical rotation of [CID] 20 ° C = -82.0° (10 mg in 1 ml of Chloroform) The (-)-(7?,RJ-5-FBVM) is thus obtained (Diagram 3).
Schéma 3 : Obtention de (-)-(R,R)-5-FBVM par hydrolyse de l’ester de Mosher 6-Di. Scheme 3: Obtaining (-)-(R,R)-5-FBVM by hydrolysis of the Mosher ester 6-Di.
• (2R,3R)-5-Fluoro-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4-tetrahvdronaphthalen- 2-ol ((ff,ff)-(-)-5-FBVM) • (2R,3R)-5-Fluoro-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahvdronaphthalen-2-ol ((ff,ff)-(-)-5-FBVM )
Dans un ballon à fond rond, le composé 6-D1 (96 mg, 0,14 mmol) a été solubilisé dans du 1 ,4-dioxane (3 mL), puis une solution aqueuse 1 M de NaOH (3 mL) a été ajoutée et le mélange réactionnel a été laissé sous agitation à 50°C pendant 18 heures. Les solvants ont été éliminés sous pression réduite, puis le brut obtenu a été solubilisé dans l'eau et extrait avec de l’AcOEt (3 x 5 mL). Les phases organiques ont été combinées et séchées sur du MgSO4. Le solvant a été éliminé sous pression réduite pour obtenir le produit souhaité (R,R)-(-)-5-FBVM sous forme de solide beige pâle (48 mg, 83%). [aD]20°c = -82.0 (10 mg in 1 mL of Chloroform). Mp: 148-149 °C. IR (v cm-1): 3379, 3062, 3027, 2937, 2919, 2848, 2798, 2771 , 1618, 1601 , 1578, 1493, 1464, 1453, 1443, 1413, 1392, 1374, 1337, 1325, 1309, 1285, 1238, 1218, 1161 ,
1137, 1074, 1052, 1022, 1003, 977, 804, 791 , 771 , 758, 710, 701 . HRMS (ESI+) : calc, pour C21H25FNO [M+H]+: 326. 19146 trouvé : 326.19131. 1H NMR (250 MHz, CDCI3) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H, 2 H-Ar), 4.34 (brs, 1 H, OH), 3.87 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.33 (dd, J = 16.2, 5.7 Hz, 1 H, H of CH2), 3.15 - 3.02 (m, 1 H, H de CH2), 3.02 - 2.84 (m, 3H, CH de CH2 et CH2), 2.83 - 2.50 (m, 4H, 2H de CH2 et 2 CH), 2.44 (td, J = 11 .5, 2.5 Hz, 1 H, H of CH2), 2.01 - 1 .86 (m, 3H, CH et H of CH2), 1.85 - 1 .62 (m, 1 H, H de CH2). 13C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2(Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7 Hz, CH), 127.0(2CH), 126.4 (CH), 124.7 (d, J = 3.3 Hz, CH), 122.7 (d, J = 17.6 Hz, Cq), 1 12.4 (d, J = 21.9 Hz, CH), 66.2 (CH), 65.4(CH), 53.8(CH2), 45.1 (CH2), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH2), 34.5 (CH2), 34.0 (CH2), 19.2 (d, J = 3.3 Hz, CH2). 19F NMR (235 MHz, CDCI3) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz). In a round-bottomed flask, compound 6-D1 (96 mg, 0.14 mmol) was dissolved in 1,4-dioxane (3 mL), then a 1 M aqueous solution of NaOH (3 mL) was added and the reaction mixture was allowed to stir at 50°C for 18 hours. The solvents were removed under reduced pressure, then the crude product obtained was dissolved in water and extracted with AcOEt (3×5 mL). The organic phases were combined and dried over MgSO4. The solvent was removed under reduced pressure to obtain the desired product (R,R)-(-)-5-FBVM as a pale beige solid (48 mg, 83%). [a D ] 20 ° C = -82.0 (10 mg in 1 mL of Chloroform). Mp: 148-149°C. IR (vcm- 1 ): 3379, 3062, 3027, 2937, 2919, 2848, 2798, 2771, 1618, 1601, 1578, 1493, 1464, 1453, 1443, 1413, 1392, 1374, 12357, 130, 130, 1392, 1374, 12357, 130, 1392 1285, 1238, 1218, 1161, 1137, 1074, 1052, 1022, 1003, 977, 804, 791, 771, 758, 710, 701. HRMS (ESI + ): calc, for C21H25FNO[M+H] + : 326.19146 found: 326.19131. 1 H NMR (250 MHz, CDCI 3 ) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H, 2H-Ar), 4.34 (brs, 1H, OH), 3.87 (td, J=10.2, 5.6Hz, 1H, CH), 3.33 (dd, J=16.2, 5.7Hz, 1H, H of CH 2 ), 3.15 - 3.02 (m, 1 H, H of CH 2 ), 3.02 - 2.84 (m, 3H, CH of CH2 and CH2), 2.83 - 2.50 (m, 4H, 2H of CH2 and 2 CH) , 2.44 (td, J = 11.5, 2.5 Hz, 1 H, H of CH 2 ), 2.01 - 1.86 (m, 3H, CH and H of CH 2 ), 1.85 - 1.62 (m, 1 H, H of CH 2 ). 13 C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2 (Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7Hz, CH), 127.0(2CH), 126.4(CH), 124.7(d, J=3.3Hz, CH), 122.7(d, J=17.6Hz, Cq), 1 12.4(d, J=21.9Hz, CH), 66.2 (CH), 65.4(CH), 53.8(CH 2 ), 45.1 (CH 2 ), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH 2 ), 34.5 (CH 2 ), 34.0 (CH 2 ), 19.2 (d, J = 3.3 Hz, CH 2 ). 19 F NMR (235 MHz, CDCI3) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz).
L’analyse de ce dernier par HPLC chirale montre qu’il s’agit effectivement d’un seul énantiomère. Analysis of the latter by chiral HPLC shows that it is indeed a single enantiomer.
De la même manière l’ester de Mosher 6-D2a été hydrolysé pour donner le (+)- (S, S 5-FBVM avec un rendement de 89%. Celui-ci a été a été analysé par polarimétrie et possède un pouvoir rotatoire de [OD]20°C = + 82.8° (10 mg dans 1 mL de Chloroforme). Son analyse HPLC chirale dans les mêmes conditions montre qu’il s’agit un seul énantiomère avec un temps de rétention plus long. In the same way, the Mosher 6-D 2 ester was hydrolyzed to give (+)- (S, S 5-FBVM with a yield of 89%. This was analyzed by polarimetry and has a optical rotation of [OD] 20 ° C .=+82.8° (10 mg in 1 mL of chloroform) Its chiral HPLC analysis under the same conditions shows that it is a single enantiomer with a longer retention time.
• (2S,3S)-5-Fluoro-3-(4-phenylpiperidin-1 -yl)-1 ,2,3,4-tetrahvdronaphthalen- 2-ol ((S,S)-(+)-5-FBVM) • (2S,3S)-5-Fluoro-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahvdronaphthalen-2-ol ((S,S)-(+)-5-FBVM )
Dans un ballon à fond rond, le composé 6-D2 (100 mg, 0,17 mmol) a été solubilisé dans du 1 ,4-dioxane (3 mL), puis une solution aqueuse 1 M de NaOH (3 mL) a été ajoutée et le mélange réactionnel a été laissé sous agitation à 50°C pendant 18 heures. Les solvants ont été éliminés sous pression réduite, puis le brut obtenu a été solubilisé dans l'eau et extrait avec de l’ AcOEt (3 x 5 ml). Les phases organiques ont été combinées et séchées sur du MgSO4. Le solvant a été éliminé sous pression réduite pour obtenir le produit souhaité (S,S)-(+)-5-FBVM sous forme de solide beige pâle (56 mg, 99 %). [aD]20°c = +82.8 (10 mg dans 1 mL de chloroforme). In a round-bottomed flask, compound 6-D2 (100 mg, 0.17 mmol) was dissolved in 1,4-dioxane (3 mL), then a 1 M aqueous solution of NaOH (3 mL) was added and the reaction mixture was allowed to stir at 50°C for 18 hours. The solvents were removed under reduced pressure, then the crude product obtained was dissolved in water and extracted with AcOEt (3 x 5 ml). The organic phases were combined and dried over MgSO4. The solvent was removed under reduced pressure to obtain the desired product (S,S)-(+)-5-FBVM as a pale beige solid (56 mg, 99%). [a D ] 20 ° C = +82.8 (10 mg in 1 mL of chloroform).
Mp :148-149 °C. IR (v cm 1): 3379, 3064, 3027, 2937, 2926, 2849, 2798, 2771 , 1619, 1601 , 1578, 1492, 1463, 1453, 1443,1413, 1392, 1374, 1337, 1325, 1309, 1285, 1238, 1218, 1 161 , 1 137, 1073, 1052, 1022, 1003, 791 , 772, 758, 711 , 701. HRMS (ESI+) : cale, pour C21 H25FNO [M+H]+: 326. 19146 trouvé : 326.19131 . 1H NMR
(250 MHz, CDCI3) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H, 2 H-Ar), 4.34 (brs, 1 H, OH), 3.87 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.33 (dd, J = 16.2, 5.7 Hz, 1 H, H of CH2), 3.15 - 3.02 (m, 1 H, H of CH2), 3.02 - 2.84 (m, 3H, CH of CH2 and CH2), 2.83 - 2.50 (m, 4H, 2H of CH2 and 2 CH), 2.44 (td, J = 11.5, 2.5 Hz, 1 H, H of CH2), 2.01 - 1 .86 (m, 3H, CH and H of CH2), 1.85 - 1 .62 (m, 1 H, H of CH2). 13C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2(Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7 Hz, CH), 127.0(2CH), 126.4 (CH), 124.7 (d, J = 3.3 Hz, CH), 122.7 (d, J = 17.6 Hz, Cq), 112.4 (d, J = 21.9 Hz, CH), 66.2 (CH), 65.4(CH), 53.8(CH2), 45.1 (CH2), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH2), 34.5 (CH2), 34.0 (CH2), 19.2 (d, J= 3.3 Hz, CH2). 19F NMR (235 MHz, CDCI3) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz). MP: 148-149°C. IR (v cm 1 ): 3379, 3064, 3027, 2937, 2926, 2849, 2798, 2771 , 1619, 1601 , 1578, 1492, 1463, 1453, 1443,1413, 1392, 1374, 1357, 1295, 1385 , 1238, 1218, 1161 , 1137, 1073, 1052, 1022, 1003, 791 , 772, 758, 711 , 701. HRMS (ESI + ): wedge, for C21 H 25 FNO [M+H] + : 326 19146 found: 326.19131 . 1 H NMR (250 MHz, CDCI 3 ) 5 7.37 - 7.17 (m, 5H, 5H-Ar), 7.1 1 (td, J = 7.9, 5.7 Hz, 1 H, H-Ar), 6.95 - 6.80 (m, 2H, 2 H-Ar), 4.34 (brs, 1 H, OH), 3.87 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.33 (dd, J = 16.2, 5.7 Hz, 1 H, H of CH 2 ), 3.15 - 3.02 (m, 1 H, H of CH 2 ), 3.02 - 2.84 (m, 3H, CH of CH2 and CH2), 2.83 - 2.50 (m, 4H, 2H of CH2 and 2 CH), 2.44 ( td, J = 11.5, 2.5 Hz, 1 H, H of CH 2 ), 2.01 - 1.86 (m, 3H, CH and H of CH 2 ), 1.85 - 1.62 (m, 1 H, H of CH 2 ). 13 C NMR (63 MHz, CDCI3) 5 161.1 (d, J = 243.9 Hz, Cq), 146.2 (Cq), 136.8 (d, J = 4.3 Hz, Cq), 128.6 (2CH), 127.4 (d, J = 8.7Hz, CH), 127.0(2CH), 126.4(CH), 124.7(d, J=3.3Hz, CH), 122.7(d, J=17.6Hz, Cq), 112.4(d, J=21.9Hz, CH ), 66.2 (CH), 65.4(CH), 53.8(CH 2 ), 45.1 (CH 2 ), 43.0 (CH), 37.9 (d, J = 2.2 Hz, CH 2 ), 34.5 (CH 2 ), 34.0 ( CH 2 ), 19.2 (d, J= 3.3 Hz, CH 2 ). 19 F NMR (235 MHz, CDCI 3 ) 5 -1 17.3 (dd, J = 9.9, 5.5 Hz).
Synthèse de l’ester boronique 8 (précurseur pour le radiomarquaqe 18F)Synthesis of the boronic ester 8 (precursor for the radiolabel 18 F)
Afin de réaliser le radiomarquage au 18F, l’ester boronique 8 a été utilisé comme précurseur (correspondant au composé de formule (III) susmentionnée). Celui-ci a été synthétisé en suivant la voie de synthèse décrite dans le schéma 4. Le composé 5-Ri Trans a été transformé in-situ en sel de diazonium correspondant par action de NaNO2 en présence de l’APTS mono-hydraté. Ce dernier conduit à l’intermédiaire iodé 7 Trans sous l’action de l’iodure de potassium présent dans le milieu réactionnel avec un rendement de 50%. Les conditions de borylation de Miyaura ont permis par la suite de transformer l’intermédiaire 7 Trans en composé 8 Trans désiré avec un rendement de 44%.
In order to carry out the radiolabeling with 18 F, the boronic ester 8 was used as precursor (corresponding to the compound of formula (III) mentioned above). This was synthesized following the synthetic route described in scheme 4. The compound 5-Ri Trans was transformed in situ into the corresponding diazonium salt by the action of NaNO 2 in the presence of the monohydrated APTS. The latter leads to the iodinated intermediate 7 Trans under the action of the potassium iodide present in the reaction medium with a yield of 50%. The Miyaura borylation conditions subsequently made it possible to transform the 7 Trans intermediate into the desired 8 Trans compound with a yield of 44%.
Schéma 4 : Synthèse du précurseur 8 Trans Scheme 4: Synthesis of the precursor 8 Trans
• 5-lodo-3-(4-DhenylDiDeridin-1 -yl)-1 ,2,3,4-tetrahvdronaDhthalen-2-ol (7)• 5-lodo-3-(4-DhenylDiDeridin-1 -yl)-1,2,3,4-tetrahvdronaDhthalen-2-ol (7)
Dans un ballon à fond rond, le composé 5-R1 (1 ,00 g, 3,10 mmol) a été solubilisé dans du CH3CN (18 ml), puis du PTSA.H2O (1 ,80 g, 9,32 mmol, 3,0 équivalents) a été ajouté en une seule fois. Le mélange a été refroidi à 0°C, puis une solution de NaNO2 (428 mg, 6,2 mmol, 2,0 équivalents) et de Kl (1 ,20 g, 7,75 mmol, 2,5 équivalents) dans de l'eau (5 mL) a été ajoutée. Après avoir été agité à 0°C pendant 15 minutes, le mélange réactionnel a été chauffé à r.t. et laissé sous agitation
pendant 4h. De I'eau (17 mL) et une solution saturée de NaHCO3 (35 ml_) ont été successivement ajoutées. La couche aqueuse a été extraite avec AcOEt (3 x 25 ml) et les phases organiques combinées ont été séchées sur du MgSC , filtrées puis séchées sous pression réduite. Le résidu a été purifié par chromatographie flash sur colonne de gel de silice (PE/AcOEt : 85/15) pour obtenir le produit souhaité 7 sous forme de solide jaunâtre (587 mg, 50%). In a round-bottom flask, compound 5-R1 (1.00 g, 3.10 mmol) was dissolved in CH 3 CN (18 ml), then PTSA.H 2 O (1.80 g, 9 .32 mmol, 3.0 equivalents) was added all at once. The mixture was cooled to 0°C, then a solution of NaNO 2 (428 mg, 6.2 mmol, 2.0 equivalents) and Kl (1.20 g, 7.75 mmol, 2.5 equivalents) in water (5 mL) was added. After being stirred at 0°C for 15 minutes, the reaction mixture was heated to rt and allowed to stir for 4 hours. Water (17 mL) and a saturated solution of NaHCO 3 (35 mL) were successively added. The aqueous layer was extracted with AcOEt (3 x 25 mL) and the combined organic phases were dried over MgSC, filtered and then dried under reduced pressure. The residue was purified by flash chromatography on a column of silica gel (PE/AcOEt: 85/15) to obtain the desired product 7 in the form of a yellowish solid (587 mg, 50%).
Rf : 0.43. 1 H NMR (250 MHz, CDCI3) ppm: 7.70 (d, J = 7.8 Hz, 1 H, 1 H-Ar), 7.39 - 7.16 (m, 6H, 6 H-Ar), 7.10 (d, J = 7.7 Hz, 1 H, 1 H-Ar), 6.83 (t, J = 7.7 Hz, 1 H, OH), 3.83 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.24 -2.33 (m, 12H, 6 CH2). Rf : 0.43. 1 H NMR (250 MHz, CDCI 3 ) ppm: 7.70 (d, J = 7.8 Hz, 1 H, 1 H-Ar), 7.39 - 7.16 (m, 6H, 6 H-Ar), 7.10 (d, J = 7.7 Hz, 1 H, 1 H-Ar), 6.83 (t, J = 7.7 Hz, 1 H, OH), 3.83 (td, J = 10.2, 5.6 Hz, 1 H, CH), 3.24 -2.33 (m, 12H, 6 CH 2 ).
• 3-(4-PhenylDiDeridin-1 -yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2,3,4-tetrahydronaphthalen-2-ol (8) : • 3-(4-PhenylDiDeridin-1 -yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydronaphthalen-2 -ol (8):
Dans un tube séché au four, le composé 7 (100 mg, 0,23 mmol) a été solubilisé dans du DMF anhydre dégazé (2 mL), puis le B2Pin2 (88 mg, 0,35 mmol, 1 ,5 équivalent), le KOAc (68 mg, 0,69 mmol, 3,0 équivalents) et le Pd(dppf)CI2.DCM (19 mg, 0,02 mmol, 0,1 équivalent) ont été ajoutés respectivement. Le tube a été scellé sous argon et chauffé à 160°C pendant 1 h30. Le mélange réactionnel a été refroidi à température ambiante puis le DMF a été séché sous pression réduite. Le résidu a été lavé avec de la saumure (20 ml) et filtré sur un tampon de célite. Le filtrat a été extrait par AcOEt (3 x 10 mL). Les phases organiques ont été combinées ensemble et séchées sur du MgSÛ4. Après élimination du solvant sous pression réduite, le résidu a été purifié par chromatographie flash sur colonne de gel de silice (PE/AcOEt : 85/15 et 5% d'Et3N) pour obtenir le produit souhaité 8 sous forme de solide blanc (50 mg, 44%). Rf : 0.27. 1H NMR (250 MHz, DMSO) ppm: 7.48 - 7.43 (m, 1 H, H-Ar), 7.33 - 7.23 (m, 4H, 4 H-Ar), 7.22 - 7.15 (m, 3H, 3 H-Ar), 4.49 (s, 1 H, OH), 3.83 (d, J = 7.8 Hz, 1 H, CH), 2.99 (ddd, J= 32.1 , 20.4, 8.7 Hz, 4H, 2 CH2), 1.81 - 1 .63 (m, 4H, 2 CH2), 1.32 (s, 12H, 4 CH3). In an oven-dried tube, compound 7 (100 mg, 0.23 mmol) was dissolved in degassed anhydrous DMF (2 mL), then B2Pin 2 (88 mg, 0.35 mmol, 1.5 equivalent) , KOAc (68 mg, 0.69 mmol, 3.0 equivalents) and Pd(dppf)Cl 2 .DCM (19 mg, 0.02 mmol, 0.1 equivalent) were added respectively. The tube was sealed under argon and heated at 160°C for 1 hour 30 minutes. The reaction mixture was cooled to ambient temperature then the DMF was dried under reduced pressure. The residue was washed with brine (20ml) and filtered through a celite pad. The filtrate was extracted with AcOEt (3 x 10 mL). The organic phases were combined together and dried over MgSO4. After removal of the solvent under reduced pressure, the residue was purified by flash chromatography on a column of silica gel (PE/AcOEt: 85/15 and 5% Et 3 N) to obtain the desired product 8 in the form of a white solid (50mg, 44%). Rf : 0.27. 1 H NMR (250 MHz, DMSO) ppm: 7.48 - 7.43 (m, 1 H, H-Ar), 7.33 - 7.23 (m, 4H, 4 H-Ar), 7.22 - 7.15 (m, 3H, 3 H- Ar), 4.49 (s, 1 H, OH), 3.83 (d, J = 7.8 Hz, 1 H, CH), 2.99 (ddd, J= 32.1, 20.4, 8.7 Hz, 4H, 2 CH 2 ), 1.81 - 1.63 (m, 4H, 2 CH 2 ), 1.32 (s, 12H, 4 CH 3 ).
Radiochimie Radiochemistry
Précédemment la radiochimie avait permis la préparation du rac (+/-)-5-FBVM Trans marqués au Fluor 18 et la séparation chirale à chaud des deux isomères qu’il contient. Il s’agit des 2 énantiomères marqués au 18F et nommés 18F E1 et 18F E2 (Schéma 5). Previously, radiochemistry had enabled the preparation of rac (+/-)-5-FBVM Trans labeled with Fluor 18 and the hot chiral separation of the two isomers it contains. These are the 2 enantiomers labeled with 18 F and named 18 F E1 and 18 F E2 (Diagram 5).
Comme toutes les analyses HPLC chirales par détection UV (chimie froide) et radio (chimie chaude) ont été réalisées sur le même support chiralpak IA, nous
pouvons donc affirmer par combinaison de ces résultats que l’isomère chaud 18F E1 correspond à l’isomère froid (-)-(R, R)-5 FBVM et le 18F E2 au (+)-(S,S)-5-FBVM. As all the chiral HPLC analyzes by UV (cold chemistry) and radio (hot chemistry) detection were carried out on the same chiralpak IA support, we can therefore affirm by combining these results that the hot isomer 18 F E1 corresponds to the cold isomer (-)-(R, R)-5 FBVM and the 18 F E2 to (+)-(S,S)- 5-FBVM.
D’après l’analyse HPLC radio analytique chirale, le temps de rétention pour (-)- (R,R)-5-[18F]FBVM = 18F E1 est 16 minutes et le temps de rétention pour (+)-(S,S)- 5-[18F]FBVM= 18F E2 est 21 minutes. According to the chiral radioanalytical HPLC analysis, the retention time for (-)- (R,R)-5-[ 18 F]FBVM = 18 F E1 is 16 minutes and the retention time for (+)- (S,S)- 5-[ 18 F]FBVM= 18 F E2 is 21 minutes.
Par effet rebond, on peut conclure qu’il y a 3 molécules marquées au 18F :By rebound effect, we can conclude that there are 3 molecules labeled with 18 F:
- la plus active et utilisable comme traceur 18F qui est le dérivé chaud (-)-(R,R)- 5-[18F]FBVM = 18F E1 (correspondant au composé de formule (I) susmentionnée),- the most active and usable as an 18 F tracer which is the hot derivative (-)-(R,R)- 5-[ 18 F]FBVM = 18 F E1 (corresponding to the compound of formula (I) above),
- l’autre diastéréoiomère (+)-(S,S)-5-[18F]FBVM = 18F E2 (correspondant au composé de formule (II) susmentionnée) et - the other diastereoiomer (+)-(S,S)-5-[ 18 F]FBVM = 18 F E2 (corresponding to the compound of formula (II) above) and
- le mélange des 2 le (+/-)-5-[18F]FBVM Trans.
- the mixture of the 2 (+/-)-5-[ 18 F]FBVM Trans.
(+/-)-5-[18F]FBVM Trans(+/-)-5-[ 18 F]FBVM Trans
Schéma 5 : Radiomarquage du dérivé 8 Trans au 18 F. Obtention des Traceurs racémiques et des traceurs énantiopurs 18 F E1 et 18 F E2 identifiés respectivement comme les (-)-(R,R)-5-r8F]FBVM et (+)-(S,S)-5-[,8F]FBVM.
Radiosvnthèse des rac-18F-5-FBVM, (R.R)-(-)- 18F-5-FBVM et (S,S)-(+)- 18F-5-FBVM Diagram 5: Radiolabeling of the 8 Trans derivative with 18 F. Obtaining racemic tracers and enantiopure tracers 18 F E1 and 18 F E2 identified respectively as (-)-(R,R)-5-r 8 F]FBVM and ( +)-(S,S)-5-[ ,8 F]FBVM. Radiosynthesis of rac-18F-5-FBVM, (RR)-(-)-18F-5-FBVM and (S,S)-(+)-18F-5-FBVM
Production des radiotraceurs Production of radiotracers
Production du (+/-) [18F]-5-FBVM Production of (+/-) [18F]-5- FBVM
Les ions fluorures [18F] sont produits à l’aide d’un cyclotron (PET trace, GE Healthcare) par irradiation d’une cible d’eau enrichie en oxygène 18 par un faisceau de protons au moyen de la réaction nucléaire 18O(p,n)18F. Les ions fluorures [18F] produits sont transférés dans un automate modifié TRACERIab FX-FN Pro (GE), passés sur une cartouche échangeuse d’anions (Waters Sep-Pak Accell Light QMA conditionnée à l’aide d’une solution de carbonate de potassium). Les ions fluorures [18F] piégés sont élués de la cartouche par 550 pL d’une solution contenant du KOTf (5 mg) et du K2CO3 (50 pg). Une distillation azéotropique est ensuite réalisé par ajout de 1 mL d’acétonitrile. L’évaporation de l’eau est réalisée à 90°C sous flux d’hélium et en dépression et cette opération est répétée par deux fois avant de réaliser la substitution nucléophile. Le précurseur 8 (2 mg) avec du Cu(OTf)2 (3.6 mg) dissous dans du DMF (960 pL) et de la pyridine (40 pL) sont ajoutés aux ions fluorures [18F], Le mélange est porté à 100°C pendant 10 min puis refroidie à 30°C et diluée avec de l’eau (8 mL). Le mélange réactionnel est passé sur une cartouche tC18 plus (Waters) puis rincée avec de l’eau (4 mL) pour piégé le produit d’intérêt et éliminer la majeure partie des composés polaires. Le (+/-) [18F]-5-FBVM est élué de la cartouche par de l’acétonitrile (2 mL) et la solution diluée avec de l’acétate d’ammonium 0,1 M (1 mL). La solution obtenue est chargée dans la boucle d’injection HPLC de l’automate et purifiée sur une colonne semi-préparative (PhenylHexyl - Phenomenex, 10 x 250 mm) avec comme phase mobile un mélange ACN/ acétate d’ammonium 0,1 M 70/30 à un débit de 4 mL.min-1. Dans ces conditions le (+/-) [18F]-5-FBVM a été collecté avec un temps de rétention de l’ordre de 11 min. La fraction collectée a été diluée avec de l’eau (30 mL) puis passée sur une cartouche a tC18 light (Waters) puis la cartouche a été rincée avec de l’eau (5 mL). Le (+/-) [18F]-5-FBVM est élué de la cartouche par de l’éthanol injectable (0,8 mL) et la formulation est complétée par l’ajout de 7,2 mL de NaCI (0,9 %). Fluoride ions [ 18 F] are produced using a cyclotron (PET trace, GE Healthcare) by irradiating a water target enriched in oxygen 18 with a beam of protons by means of the nuclear reaction 18 O (p,n) 18 F. The [ 18 F] fluoride ions produced are transferred to a modified TRACERIab FX-FN Pro (GE) automaton, passed over an anion exchange cartridge (Waters Sep-Pak Accell Light QMA conditioned with using a solution of potassium carbonate). The trapped [ 18 F] fluoride ions are eluted from the cartridge by 550 μL of a solution containing KOTf (5 mg) and K2CO3 (50 μg). Azeotropic distillation is then carried out by adding 1 mL of acetonitrile. The evaporation of the water is carried out at 90° C. under helium flow and under depression and this operation is repeated twice before carrying out the nucleophilic substitution. Precursor 8 (2 mg) with Cu(OTf) 2 (3.6 mg) dissolved in DMF (960 pL) and pyridine (40 pL) are added to the fluoride ions [ 18 F], The mixture is brought to 100 °C for 10 min then cooled to 30°C and diluted with water (8 mL). The reaction mixture is passed through a tC18 plus cartridge (Waters) then rinsed with water (4 mL) to trap the product of interest and eliminate most of the polar compounds. The (+/-) [ 18 F]-5-FBVM is eluted from the cartridge with acetonitrile (2 mL) and the solution diluted with 0.1 M ammonium acetate (1 mL). The solution obtained is loaded into the HPLC injection loop of the automaton and purified on a semi-preparative column (PhenylHexyl - Phenomenex, 10 x 250 mm) with an ACN/0.1 M ammonium acetate mixture as mobile phase. 70/30 at a flow rate of 4 mL.min -1 . Under these conditions the (+/-) [ 18 F]-5-FBVM was collected with a retention time of the order of 11 min. The fraction collected was diluted with water (30 mL) then passed through a tC18 light cartridge (Waters) then the cartridge was rinsed with water (5 mL). The (+/-) [ 18 F]-5-FBVM is eluted from the cartridge with injectable ethanol (0.8 mL) and the formulation is completed by adding 7.2 mL of NaCl (0. 9%).
Production du (-) [18F]-5-FBVM et (+) [18F]-5-FBVM Production of (-) [ 18 F]-5-FBVM and (+) [ 18 F]-5-FBVM
La production des énantiomères isolés (+) [18F]-5-FBVM et (-) [18F]-5-FBVM se déroule en suivant le procédé de fabrication du (+/-) [18F]-5-FBVM en y ajoutant une purification chirale HPLC.
La fraction pure collectée de (+/-) [18F]-5-FBVM est chargée dans la boucle HPLC de l’automate pour réaliser une nouvelle purification HPLC, cette fois ci sur une colonne semi-préparative chirale (Chriralpak IA , Daicel, 10x250 mm). La phase mobile utilisée se compose d’acétonitrile/ acétate d’ammonium : 0.1 M 85/15 et la purification est effectuée à 4 mL.min-1. Dans ces conditions le (-) [18F]-5-FBVM est collecté avec un temps de rétention de 18 min environ quand le (+) [18F]-5-FBVM présente un temps de rétention d’environ 22 min. Par cette méthode, chaque énantiomère pur peut être produit séparément. La fraction énantiomériquement pure collectée, le (-) ou (+) [18F]-5-FBV, est diluée avec de l’eau (30 mL) puis passée sur une cartouche a tC18 light (Waters). Lia cartouche est rincée avec de l’eau (5 mL). Le (-) [18F]-5-FBVM ou (+) [18F]-5-FBVM est élué de la cartouche par de l’éthanol injectable (0,8 mL) et la formulation est complétée par l’ajout de 7,2 mL de NaCI (0,9 %). The production of the isolated (+)[18F]-5- FBVM and (-)[18F]-5- FBVM enantiomers follows the manufacturing process of (+/-)[18F]-5- FBVM by adding a chiral HPLC purification. The collected pure fraction of (+/-) [ 18 F]-5-FBVM is loaded into the HPLC loop of the automaton to carry out a new HPLC purification, this time on a chiral semi-preparative column (Chriralpak IA, Daicel , 10x250mm). The mobile phase used consists of acetonitrile/ammonium acetate: 0.1 M 85/15 and the purification is carried out at 4 mL.min −1 . Under these conditions the (-) [ 18 F]-5-FBVM is collected with a retention time of approximately 18 min when the (+) [ 18 F]-5-FBVM exhibits a retention time of approximately 22 min. By this method, each pure enantiomer can be produced separately. The enantiomerically pure fraction collected, the (-) or (+) [ 18 F]-5-FBV, is diluted with water (30 mL) then passed through a tC18 light cartridge (Waters). The cartridge is rinsed with water (5 mL). The (-) [ 18 F]-5-FBVM or (+) [ 18 F]-5-FBVM is eluted from the cartridge by injectable ethanol (0.8 mL) and the formulation is completed by adding of 7.2 mL of NaCl (0.9%).
Production du (-)-(R,R)-[18F]-5-FBVM avec une seule purification HPLCProduction of (-)-(R,R)-[ 18 F]-5-FBVM with a single HPLC purification
Comme le composé le plus actif identifié est le (-)-(R,R)-[18F]-5-FBVM et qu’il correspond au premier composé élué lors de la purification chirale HPLC, le procédé de fabrication a été modifiée de manière à n’avoir qu’une seule purification HPLC. As the most active compound identified is (-)-(R,R)-[ 18 F]-5-FBVM and it corresponds to the first compound eluted during chiral HPLC purification, the manufacturing process has been modified so as to have only one HPLC purification.
Le procédé reprend celui décrit plus haut jusqu’à l’étape de purification. La solution brute de (+/-) [18F]-5-FBVM est chargée dans la boucle HPLC et injectée sur la colonne chirale (Chiralpak IA , Daicel, 10x250 mm). La purification est réalisée en utilisant une mélange acétonitrile/méthanol/ acétate d’ammonium 0,1 M : 70/10/20 comme phase mobile et à un débit de 4 mL/min. Dans ces conditions le temps de rétention du (-)-(R,R)-[18F]-5-FBVM de l’ordre de 14,5 min. La formulation reprend les procédés présentés ci-dessus. The process repeats that described above up to the purification stage. The crude solution of (+/-) [ 18 F]-5-FBVM is loaded into the HPLC loop and injected onto the chiral column (Chiralpak IA, Daicel, 10×250 mm). The purification is carried out using a mixture of acetonitrile/methanol/0.1 M ammonium acetate: 70/10/20 as mobile phase and at a flow rate of 4 mL/min. Under these conditions, the retention time of (-)-(R,R)-[18F]-5- FBVM of the order of 14.5 min. The formulation incorporates the methods presented above.
Contrôle qualité des radiotraceurs Quality control of radiotracers
Les radiotraceurs ont été contrôlés par HPLC analytique équipée d'un détecteur UV et radio. La pureté (+/-) [18F]-5-FBVM a été vérifiée à l'aide d'une colonne analytique (Phenomenex Luna 5p Phenyl Hexyl 4,6x250 mm ) utilisant de l'ACN/Ac Am 0,1 M 70/30 comme phase mobile et un débit de 1 mL/min. Dans ces conditions, le temps de rétention est de 9 min. The radiotracers were controlled by analytical HPLC equipped with a UV and radio detector. The purity (+/-) [18F]-5-FBVM was checked using an analytical column (Phenomenex Luna 5p Phenyl Hexyl 4.6x250 mm) using ACN/Ac Am 0.1 M 70 /30 as mobile phase and a flow rate of 1 mL/min. Under these conditions, the retention time is 9 min.
Dans le cas d'une purification énantiomérique, en plus du contrôle précédent et d'un contrôle CLHP utilisant une colonne chirale (Chiralpak IA 4,6 x 250 mm 5 p), on peut évaluer la pureté énantiomérique de (+) [18F]-5-FBVM ou (-) [18F]-5-FBVM.
Pour ce contrôle, l'ACN/Ac Am 0,1 M 85/15 a été utilisé comme phase mobile à un débit de 1 ml/min. Dans ces conditions, le temps de rétention de (-) [18F]-5-FBVM ou (+) [18F]-5-FBVM était respectivement de 16,2 et 21 ,1 min. In the case of enantiomeric purification, in addition to the previous control and an HPLC control using a chiral column (Chiralpak IA 4.6 x 250 mm 5 p), one can evaluate the enantiomeric purity of (+) [18F] -5-FBVM or (-) [18F]-5-FBVM. For this control, ACN/Ac Am 0.1 M 85/15 was used as mobile phase at a flow rate of 1 ml/min. Under these conditions, the retention time of (-) [18F]-5-FBVM or (+) [18F]-5-FBVM was 16.2 and 21.1 min, respectively.
Pour tous les composés, la pureté radiochimique était supérieure à 99 %, l'activité molaire supérieure à 100 GBq/pmole et aucune dégradation n'a été observée dans les milieux de formulation comme dans le sérum pendant au moins 4h. For all the compounds, the radiochemical purity was greater than 99%, the molar activity greater than 100 GBq/pmole and no degradation was observed in the formulation media as in the serum for at least 4 h.
Biologie Biology
Biologie in vitro In vitro biology
La mesure de l’affinité des différents composés pour le VAChT a été réalisée par méthode de radioliaison sur preparation memebranaire de cerveau de rat selon la méthode décrite dans Scheunemann et al. (Bioorg Med Chem 2004;12:1459-65). Le L-(-)-vesamicol provenait de Sigma Aldrich (Saint-Quentin-Fallavier, France) et le [3H]vesamicol (activité spécifique 1705.7 GBq/mmol) de Perkin-Elmer (Courtaboeuf, France). Les valeurs d’IC5o ont été déterminées graphiquement pour chaque composé et le Ki (constante d’inhibition) a été calculé selon la méthode de Cheng & Prussoff (Biochemical pharmacology 1973;22:3099-108). Les résultats sont exprimés en moyenne des Ki ± écart type à la moyenne à partir de 3 expériences indépendantes. The measurement of the affinity of the various compounds for VChT was carried out by radiolinking method on a rat brain membrane preparation according to the method described in Scheunemann et al. (Bioorg Med Chem 2004;12:1459-65). L-(-)-vesamicol was from Sigma Aldrich (Saint-Quentin-Fallavier, France) and [ 3H ]vesamicol (specific activity 1705.7 GBq/mmol) from Perkin-Elmer (Courtaboeuf, France). The IC 50 values were determined graphically for each compound and the Ki (inhibition constant) was calculated according to the method of Cheng & Prussoff (Biochemical pharmacology 1973;22:3099-108). The results are expressed as the mean of Ki ± standard deviation from the mean from 3 independent experiments.
Par complémentarité les valeurs des affinités des trois produits fluorés froids ont été assignées : rac (+/-)-5-FBVM Trans : Ki = 1 .3 +/-0.2 nM By complementarity, the affinity values of the three cold fluorinated products have been assigned: rac (+/-)-5-FBVM Trans: Ki = 1.3 +/-0.2 nM
(-)- /?, H 5-FBVM E1 : Ki = 0.9 +/- 0.3 nM (-)-/?, H 5-FBVM E1: Ki = 0.9 +/- 0.3 nM
(+)-(S,S)-5-FBVM. E2: Ki = 35 +/- 5 nM (+)-(S,S)-5-FBVM. E2: Ki = 35 +/- 5nM
En comparaison le Ki du (-)-FEOBV est de Ki= 61 ±2.8 nM selon les mêmes conditions expérimentales. In comparison, the Ki of (-)-FEOBV is Ki=61±2.8 nM under the same experimental conditions.
Biologie in vivo In-vivo biology
Démonstrations expérimentales réalisées Experimental demonstrations carried out
La présente invention basée sur la structure de molécules de type (benzo)vesamicol permet d’atteindre un bon niveau de spécificité in vitro, et le premier radioligand (rac (+/-)-5-FBVM T rans) a démontré son potentiel comme traceur TEP in vivo chez le rat au regard de son excellent passage de la barrière hémato-
encéphalique, de son accumulation spécifique dans les régions cérébrales où sont localisés les VAChT et de sa bonne stabilité in vivo. The present invention based on the structure of molecules of the (benzo)vesamicol type makes it possible to achieve a good level of specificity in vitro, and the first radioligand (rac (+/-)-5-FBVM T rans) has demonstrated its potential as PET tracer in vivo in rats with regard to its excellent passage through the blood- encephalon, its specific accumulation in the cerebral regions where the VAChTs are located and its good stability in vivo.
De plus, les 2 isomères du [18F]FBVM racémique ont été séparés, obtenant ainsi le (-)-(H,fî,)-5-FBVM 18F E1 et le (+)-(S,S)-5-[18F]FBVM 18F E2. Il a été montré que le (-)- F?,F? 5-FBVM 18F E1 est supérieur en termes de passage de la barrière hémato-encéphalique et de liaison au VAChT que le racémique et l’autre isomère. In addition, the 2 isomers of racemic [ 18 F]FBVM were separated, thus obtaining (-)-(H,fî,)-5-FBVM 18 F E1 and (+)-(S,S)-5 -[ 18 F]FBVM 18 F E2. It has been shown that the (-)- F?,F? 5-FBVM 18 F E1 is superior in terms of crossing the blood-brain barrier and binding to VAChT than the racemate and the other isomer.
En effet dans le striatum, région cérébrale connue pour être la plus dense en VAChT, le pourcentage de dose de traceur injecté par gramme de tissu (%DI/g) est le plus élevé pour le (-)-(R,R)-5-FBVM 18F E1 (Tableau 1 ). Les valeurs obtenues pour les rapports d’accumulation entre le striatum et le cervelet, connu comme zone de référence pour la fixation non-spécifique car dépourvu de VAChT, démontrent également la supériorité du (+)-(S,S)-5-[18F]FBVM 18F E2 par rapport à l’autre isomère, (-)-(R,R)-5-FBVM 18F E1 , et le racémique [18F]FBVM. Indeed in the striatum, brain region known to be the most dense in VAChT, the percentage of tracer dose injected per gram of tissue (%DI/g) is the highest for (-)-(R,R)- 5-FBVM 18 F E1 (Table 1). The values obtained for the accumulation ratios between the striatum and the cerebellum, known as a reference zone for non-specific binding because it lacks VAChT, also demonstrate the superiority of (+)-(S,S)-5-[ 18 F]FBVM 18 F E2 compared to the other isomer, (-)-(R,R)-5-FBVM 18 F E1 , and the racemate [ 18 F]FBVM.
Tableau 1 : Accumulation cérébrale des traceurs chez le rat
Table 1: Cerebral accumulation of tracers in rats
Les résultats sont exprimés en pourcentage de la dose injectée/g de tissu cérébra (%DI/g) ± SEM, 2 heures après injection i.v. des traceurs ; n=6/groupe. The results are expressed as a percentage of the injected dose/g of brain tissue (%DI/g) ± SEM, 2 hours after i.v. injection of the tracers; n=6/group.
Il a également été montré que la fixation cérébrale du (-)- F?,F?>5-FBVM 18F E1 est bien spécifique du VAChT, puisqu’elle est fortement inhibée chez les animaux dont ces sites ont été occupés par l’administration d’un ligand connu du VAChT. En effet, dans le striatum, l’accumulation du (-)- F?,F? 5-FBVM 18F E1 est diminuée de 46% chez les animaux ayant reçu une dose de 0.5 pmole/kg de (-)vesamicol 5 minutes avant injection du traceur. It has also been shown that the cerebral uptake of (-)-F?,F?>5-FBVM 18 F E1 is very specific for VAChT, since it is strongly inhibited in animals whose sites have been occupied by the administration of a known VChT ligand. Indeed, in the striatum, the accumulation of (-)-F?,F? 5-FBVM 18 F E1 is reduced by 46% in animals having received a dose of 0.5 pmol/kg of (-)vesamicol 5 minutes before injection of the tracer.
Dans une seconde étape, les inventeurs ont comparé, dans le même protocole expérimental chez le rat, le (-)- F?,F?>5-FBVM 18F E1 avec le traceur décrit dans la littérature, le [18F]FEOBV, dont le radiomarquage a été réalisé sur site. In a second step, the inventors compared, in the same experimental protocol in rats, (-)-F?,F?>5-FBVM 18 F E1 with the tracer described in the literature, [ 18 F]FEOBV , whose radiolabeling was carried out on site.
Les résultats (Tableau 2) démontrent une plus forte accumulation du (-)-(R,R)- 5-FBVM 18F E1 comparé au [18F]FEOBV dans le striatum, avec un ratio signal/bruit (= striatum/cervelet) supérieur pour le (-)-(R,R)-5-FBVM E1 que pour le [18F]FEOBV.
Tableau 2 : Accumulation cérébrale du (-)-(fî,fî)-5-FBVM E1 et du [18F]FEOBV
The results (Table 2) demonstrate a greater accumulation of (-)-(R,R)-5-FBVM 18 F E1 compared to [ 18 F]FEOBV in the striatum, with a signal/noise ratio (= striatum/cerebellum ) higher for (-)-(R,R)-5-FBVM E1 than for [ 18 F]FEOBV. Table 2: Cerebral accumulation of (-)-(fî,fî)-5-FBVM E1 and [ 18 F]FEOBV
Les résultats sont exprimés en pourcentage de a dose injectée/g de tissu cérébral (%DI/g) ± SEM, 2 heures après injection i.v. des traceurs ; n=6/groupe. The results are expressed as a percentage of a dose injected/g of brain tissue (%DI/g) ± SEM, 2 hours after i.v. injection of the tracers; n=6/group.
Modes opératoires in vivo des rac-5-FBVM, (R,R)-(-)-5FBVM et (S,S)-(+)- 5FBVM In vivo operating modes of rac-5-FBVM, (R,R)-(-)-5FBVM and (S,S)-(+)-5FBVM
Animaux : Les expériences ont été réalisées chez des rat mâles de souche Wistar pesant 250-300 g (Centre d’Elevage R. Janvier, Le Genest St Isle, France). Toutes les procédures ont été réalisées dans le respect de la règlementation Européenne concernant l’expérimentation animale (2010/63/EU) avec l’autorisation du Comité Régional d’Ethique en Expérimentation Animale. Animals: The experiments were carried out on male rats of the Wistar strain weighing 250-300 g (Centre d'Elevage R. Janvier, Le Genest St Isle, France). All procedures were carried out in compliance with European regulations concerning animal experimentation (2010/63/EU) with the authorization of the Regional Ethics Committee for Animal Experimentation.
Etudes de biodistribution: Les rats du groupe témoin ont reçu une injection i.v. de traceur (4-6 MBq dans 0.3 mL) sous anesthésie gazeuse à l’isofurane (n= 6/groupe). Dans le groupe VES (n=6/groupe), l’injection du traceur a été précédée (5 min) d’une injection i.v. de vesamicol (0.5 pmol/kg). Les rats ont été sacrifiés par décapitation à 2 h post injection du traceur. Le cerveau entier est prélevé puis disséqué en différentes zones : cortex, striatum, hippocampus, thalamus et cerebellum. Des fractions sanguine et osseuse sont également prélevées. Les échantillons biologiques sont ensuite pesés et leur radioactivité est mesurée avec un compteur y (2480 Gamma counter Wizard, Perkin Elmer), et le pourcentage de dose injectée/ g de tissu (%ID/g) est calculé.. Biodistribution studies: Rats in the control group received an i.v. injection of tracer (4-6 MBq in 0.3 mL) under isofuran gas anesthesia (n= 6/group). In the VES group (n=6/group), the injection of the tracer was preceded (5 min) by an i.v. injection of vesamicol (0.5 pmol/kg). The rats were sacrificed by decapitation 2 h after injection of the tracer. The whole brain is removed and then dissected into different areas: cortex, striatum, hippocampus, thalamus and cerebellum. Blood and bone fractions are also taken. The biological samples are then weighed and their radioactivity is measured with a y counter (2480 Gamma counter Wizard, Perkin Elmer), and the percentage of injected dose/g of tissue (%ID/g) is calculated.
Imagerie TEP: Les rats ont reçu une injection i.v. de 37 MBq du traceur. Les acquisitions ont été réalisées avec un système d’imagerie microPET explore VISTA- CT system (GE Healthcare, France) sous anesthésie à l’isoflurane (Baxter, France), à 4-5% dans oxygène pour l’induction puis 1 .5-2% pendant l’enregistrement. Chaque acquisition a duré 91 minutes et les images ont été séquencées en list-mode en 1 séquence de 1 min suivie de 9 séquences de s of 10 min. Après correction d’atténuation, les images ont été reconstruites selon un algorithme 2-D OSEM (GE Healthcare, France) en voxels de 0.3875 x 0.3875 x 0.775 mm3.
PET imaging: The rats received an iv injection of 37 MBq of the tracer. The acquisitions were carried out with a microPET explore VISTA-CT system imaging system (GE Healthcare, France) under isoflurane anesthesia (Baxter, France), at 4-5% in oxygen for induction then 1.5 -2% while recording. Each acquisition lasted 91 minutes and the images were sequenced in list-mode in 1 sequence of 1 min followed by 9 sequences of 10 min. After attenuation correction, the images were reconstructed according to a 2-D OSEM algorithm (GE Healthcare, France) in voxels of 0.3875×0.3875×0.775 mm 3 .
Claims
1 . Composé répondant à la formule (I) suivante :
1 . Compound corresponding to the following formula (I):
2. Composé de formule (I) selon la revendication 1 , pour utilisation dans une méthode de diagnostic in vivo. 2. Compound of formula (I) according to claim 1, for use in an in vivo diagnostic method.
3. Composé de formule (I) selon la revendication 1 , pour utilisation dans une méthode de diagnostic in vivo d’une maladie neurodégénérative cholinergique. 3. Compound of formula (I) according to claim 1, for use in an in vivo diagnostic method for a cholinergic neurodegenerative disease.
4. Composé de formule (I) pour son utilisation selon la revendication 3, dans laquelle la maladie neurodégénérative cholinergique est choisie dans le groupe constitué de la maladie d’Alzheimer, de la dysmnésie, du trouble d’apprentissage, de la schizophrénie, du dysfonctionnement cognitif, du trouble d’hyperactivité, de la névrose d’angoisse, de la dépression, de l’analgésie et de la maladie de Parkinson. 4. Compound of formula (I) for its use according to claim 3, in which the cholinergic neurodegenerative disease is chosen from the group consisting of Alzheimer's disease, dysmnesia, learning disability, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgesia and Parkinson's disease.
5. Procédé de préparation du composé de formule (I) selon la revendication 1 , comprenant une étape (a) de préparation d’un mélange réactionnel par l’addition d’un composé de formule (III) suivante :
avec des ions fluor réactifs 18F,
suivie d’une étape (b) de séparation chirale dudit mélange réactionnel obtenu à l’issue de l’étape (a). 5. A process for preparing the compound of formula (I) according to claim 1, comprising a step (a) of preparing a reaction mixture by adding a compound of the following formula (III): with reactive fluorine ions 18 F, followed by a step (b) of chiral separation of said reaction mixture obtained at the end of step (a).
6. Procédé selon la revendication 5, dans lequel l’étape (b) de séparation chirale est effectuée par chargement du mélange réactionnel obtenu à l’issue de l’étape (a) sur une colonne chirale semi-préparative en utilisant une phase mobile chirale comprenant un mélange d’acétonitrile, d’acétate d’ammonium et de méthanol. 6. Process according to claim 5, in which step (b) of chiral separation is carried out by loading the reaction mixture obtained at the end of step (a) onto a semi-preparative chiral column using a mobile phase chiral comprising a mixture of acetonitrile, ammonium acetate and methanol.
7. Procédé selon la revendication 6, dans lequel la phase mobile comprend de 50% à 90% en volume d’acétonitrile, de 0% à 20% en volume d’acétate d’ammonium et de 0% à 40% en volume de méthanol, par rapport au volume total de ladite phase mobile, de préférence 70% en volume d’acétonitrile, 10% en volume d’acétate d’ammonium et 20% en volume de méthanol, par rapport au volume total de ladite phase mobile. 7. Process according to claim 6, in which the mobile phase comprises from 50% to 90% by volume of acetonitrile, from 0% to 20% by volume of ammonium acetate and from 0% to 40% by volume of methanol, relative to the total volume of said mobile phase, preferably 70% by volume of acetonitrile, 10% by volume of ammonium acetate and 20% by volume of methanol, relative to the total volume of said mobile phase.
8. Procédé selon l’une quelconque des revendications 5 à 7, dans lequel le composé de formule (III) est obtenu selon un procédé comprenant les étapes suivantes : 8. Method according to any one of claims 5 to 7, in which the compound of formula (III) is obtained according to a method comprising the following steps:
- la réaction de diazotation d’un composé de formule (IV) suivante :
suivie d’une réaction de substitution par un halogène, tel que l’iode, sur le composé diazo obtenu à l’issue de la réaction de diazotation susmentionnée, ladite étape étant de préférence une étape de réaction du composés de formule (IV) avec du nitrite de sodium, notamment en présence de l’APTS mono-hydraté, suivie de l’addition d’iodure de potassium,
pour obtenir un composé de formule (V) suivante :
- the diazotization reaction of a compound of formula (IV) below: followed by a substitution reaction with a halogen, such as iodine, on the diazo compound obtained at the end of the aforementioned diazotization reaction, said step preferably being a step of reacting the compounds of formula (IV) with sodium nitrite, in particular in the presence of the mono-hydrated APTS, followed by the addition of potassium iodide, to obtain a compound of the following formula (V):
- la transformation du composé de formule (V) par borylation de Miyaura pour obtenir un composé de formule (III). - the transformation of the compound of formula (V) by borylation of Miyaura to obtain a compound of formula (III).
9. Composé répondant à la formule (II) suivante :
9. Compound corresponding to the following formula (II):
10. Composé répondant à la formule (III) suivante :
10. Compound corresponding to the following formula (III):
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/253,953 US20240058481A1 (en) | 2020-11-23 | 2021-11-23 | Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases |
| CA3198747A CA3198747A1 (en) | 2020-11-23 | 2021-11-23 | Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases |
| EP21811091.4A EP4247437A1 (en) | 2020-11-23 | 2021-11-23 | Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2012024A FR3116433B1 (en) | 2020-11-23 | 2020-11-23 | RADIOLABELED COMPOUNDS FOR THE DIAGNOSIS OF CHOLINERGIC NEURODEGENERATIVE DISEASES |
| FRFR2012024 | 2020-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022106714A1 true WO2022106714A1 (en) | 2022-05-27 |
Family
ID=74183410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2021/082619 WO2022106714A1 (en) | 2020-11-23 | 2021-11-23 | Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240058481A1 (en) |
| EP (1) | EP4247437A1 (en) |
| CA (1) | CA3198747A1 (en) |
| FR (1) | FR3116433B1 (en) |
| WO (1) | WO2022106714A1 (en) |
-
2020
- 2020-11-23 FR FR2012024A patent/FR3116433B1/en active Active
-
2021
- 2021-11-23 EP EP21811091.4A patent/EP4247437A1/en active Pending
- 2021-11-23 US US18/253,953 patent/US20240058481A1/en active Pending
- 2021-11-23 WO PCT/EP2021/082619 patent/WO2022106714A1/en active Application Filing
- 2021-11-23 CA CA3198747A patent/CA3198747A1/en active Pending
Non-Patent Citations (18)
| Title |
|---|
| AGHOURIAN ET AL., MOL PSYCHIATRY, vol. 22, no. 11, November 2017 (2017-11-01), pages 1531 - 1538 |
| AGHOURIAN M ET AL: "Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV", vol. 22, no. 11, 1 November 2017 (2017-11-01), GB, pages 1531 - 1538, XP055822741, ISSN: 1359-4184, Retrieved from the Internet <URL:https://www.nature.com/articles/mp2017183.pdf> [retrieved on 20210708], DOI: 10.1038/mp.2017.183 * |
| CHENGPRUSSOFF, BIOCHEMICAL PHARMACOLOGY, vol. 22, 1973, pages 3099 - 108 |
| DURAND ET AL., AM J PHYSIOL HEART CIRC PHYSIOL., vol. 309, no. 4, 15 August 2015 (2015-08-15), pages H655 - 62 |
| KILBOURN M R ET AL: "Mouse brain distribution of a carbon-11 labeled vesamicol derivative: Presynaptic marker of cholinergic neurons", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 47, no. 21, 1 January 1990 (1990-01-01), pages 1955 - 1963, XP025525988, ISSN: 0024-3205, [retrieved on 19900101], DOI: 10.1016/0024-3205(90)90408-J * |
| KOTAGAL ET AL., NEUROSCI LETT, vol. 514, no. 2, 18 April 2012 (2012-04-18), pages 169 - 72 |
| KOVAC M ET AL: "3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT)", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 21, 1 November 2010 (2010-11-01), pages 7659 - 7667, XP027415420, ISSN: 0968-0896, [retrieved on 20100817] * |
| KUHL ET AL., ANN NEUROL, vol. 40, no. 3, September 1996 (1996-09-01), pages 399 - 410 |
| MAZÈRE ET AL., J NUCL MED, vol. 58, no. 1, January 2017 (2017-01-01), pages 123 - 128 |
| MAZÈRE ET AL., NEUROIMAGE CLIN, vol. 3, 8 August 2013 (2013-08-08), pages 212 - 7 |
| MAZÈRE ET AL., NEUROIMAGE, vol. 40, no. 1, 1 March 2008 (2008-03-01), pages 280 - 8 |
| MAZÈRE ET AL., RADIOLOGY, vol. 265, no. 2, November 2012 (2012-11-01), pages 537 - 43 |
| NEJAD-DAVARANI ET AL., MOL PSYCHIATRY, vol. 24, no. 3, March 2019 (2019-03-01), pages 322 - 327 |
| PETROU MYRIA ET AL: "In Vivo Imaging of Human Cholinergic Nerve Terminals with (-)-5- 18 F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses", vol. 55, no. 3, 1 March 2014 (2014-03-01), US, pages 396 - 404, XP055822562, ISSN: 0161-5505, Retrieved from the Internet <URL:https://jnm.snmjournals.org/content/jnumed/55/3/396.full.pdf> [retrieved on 20210707], DOI: 10.2967/jnumed.113.124792 * |
| SCHEUNEMANN ET AL., BIOORG MED CHEM, vol. 12, 2004, pages 1459 - 65 |
| STEPHEN ET AL., J ALZHEIMERS DIS, vol. 59, no. 2, 2017, pages 695 - 705 |
| STOKHOLM ET AL., EUR J NUCL MED MOL IMAGING, vol. 43, no. 5, May 2016 (2016-05-01), pages 906 - 910 |
| SULTZER ET AL., BRAIN, vol. 141, no. 3, 1 March 2018 (2018-03-01), pages 626 - 628 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3116433B1 (en) | 2023-12-15 |
| CA3198747A1 (en) | 2022-05-27 |
| US20240058481A1 (en) | 2024-02-22 |
| FR3116433A1 (en) | 2022-05-27 |
| EP4247437A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8318132B2 (en) | Imaging agents for detecting neurological dysfunction | |
| US20150030540A1 (en) | Imaging agents for detecting neurological dysfunction | |
| KR20200013236A (en) | Novel deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological applications | |
| RU2524214C2 (en) | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission | |
| EP3003399B1 (en) | Novel chemical compounds derived from normemantine and use of same in the medical field | |
| WO2022106714A1 (en) | Radiolabelled compounds for diagnosing cholinergic neurodegenerative diseases | |
| Rogers et al. | 18F-labelled vesamicol derivatives: syntheses and preliminary in vivo small animal positron emission tomography evaluation | |
| Kanegawa et al. | Synthesis and evaluation of radioiodinated (S, S)-2-(α-(2-iodophenoxy) benzyl) morpholine for imaging brain norepinephrine transporter | |
| EP0901491B1 (en) | Tropane derivatives useable in particular for in vivo detection of dopamine transporters | |
| CN108047145B (en) | 2-arylquinoxaline compound with affinity with Tau protein and preparation method and application thereof | |
| JP3728376B2 (en) | Muscarinic Acetylcholine Nervous System Labeled Compound and Method for Synthesis | |
| KR101828868B1 (en) | Synthesis method of 5-HT2C receptor-specific PET radiotracer | |
| AU708504B2 (en) | Novel heterocyclic compounds for the treatment of pain and use thereof | |
| KR102533957B1 (en) | Methods for Different Solubility-Directed Asymmetric Conversions of Substituted 2H-Chromene-3-Carboxylic Acids | |
| WO2011159870A9 (en) | Methods and compounds for the preparation of fluorine-labeled deoxy-fty720 | |
| JP6273251B2 (en) | Aromatic amino acid derivative and PET probe using the same | |
| JP2007501848A (en) | 1-carbamoylcycloalkylcarboxylic acid compound, process for producing the same, and use thereof | |
| JPH0816084B2 (en) | Process for producing optically active phenylethylamine derivative | |
| Maisonial-Besset et al. | Improved automated one-pot two-step radiosynthesis of (S)-[18F] FETrp, a radiotracer for PET imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) | |
| 김호영 | Development of serotonin metabolism PET imaging agents using 18F-labeled tryptophan derivatives | |
| JP4592869B2 (en) | Muscarinic acetylcholine nervous system labeled compound and method for producing the same | |
| KR100287365B1 (en) | Preparation of raclopride derivative having n2s2ligand | |
| Patel | Cyclodextrin assisted enantiomeric recognition of amino acid imides and toward synthesis of dolabellane diterpenoid B | |
| FR2527210A1 (en) | ENANTIOMERS OF HEXAHYDRO-2,3,3A, 4,5,6 1H-INDOLO (3,2,1-DE) (NAPHTHYRIDINE-1,5), THEIR SEPARATION METHOD AND THEIR THERAPEUTIC APPLICATION | |
| Hashimoto et al. | Radiosynthesis of [18F] N‐(4‐phenylbutyl)‐4‐(4‐fluorobenzoyl) piperidine for studying serotonin 5‐HT2a receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21811091 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3198747 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18253953 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2021811091 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021811091 Country of ref document: EP Effective date: 20230623 |